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ABSTRACT 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and a common 
cause of dementia worldwide. The pathogenic mechanisms of AD are not completely 
understood. Both genetic and external factors, like lifestyle and other diseases, can alter 
AD risk. The impact of external factors may be mediated by epigenetic mechanisms, like 
DNA methylation. The first clinical symptoms of AD usually manifest as episodic 
memory impairment (EMI), however, AD can be diagnosed only at a later stage when 
neurodegeneration is far-progressed. New methods are required to enable early diagnosis 
and characterization of the disease mechanisms. 
The main goals of this study were to implement new methods for characterization 
of disease marks and mechanisms and to identify new DNA methylation marks for 
EMI and AD with these methods. Reduced Representation Bisulfite Sequencing 
(RRBS) was first implemented by utilising human embryonic stem cells and by 
identifying DNA methylation changes in these cells during transformation to abnormal 
karyotype. RRBS was then utilised to identify blood DNA methylation marks for AD 
in Finnish disease discordant twin pairs. Such marks were detected in eleven genomic 
regions and the one in adenosine deaminase RNA specific B2 gene (ADARB2) was 
validated in Swedish twin cohorts. A new twin sample cohort was collected and 
genome-wide bisulphite sequencing method was implemented to identify plasma cell-
free DNA methylation marks for EMI. No markers were detected. Patient-specific 
induced pluripotent stem cell lines and a brain organoid model were generated to study 
the pathogenic mechanisms of AD. 
In conclusion, the results show that DNA methylation marks associated with AD 
can be detected not only in the brain but also in blood, however, more research is 
required to evaluate whether these marks can be utilised in diagnostics. Several 
methods enabling identification of disease marks were successfully implemented, 
samples from a new cohort were collected and pluripotent stem cell-based model 
was established to study AD. These resources will be valuable for future research 
aiming to identify mechanisms and markers for AD. 
KEYWORDS: Alzheimer’s disease, blood biomarkers, epigenomics, DNA 
methylation, human pluripotent stem cells, disease model.  
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TURUN YLIOPISTO 
Lääketieteellinen tiedekunta 
Lääketieteellinen biokemia ja genetiikka 
MIKKO KONKI: Uusien menetelmien käyttöönotto Alzheimerin tautiin ja 
episodisen muistin heikkenemiseen liittyvien DNA-metylaatiomarkkereiden 
tunnistamiseksi 
Väitöskirja, 112 s. 
Molekyylilääketieteen tohtoriohjelma 
Turku Bioscience Centre 
Syyskuu 2020 
TIIVISTELMÄ 
Alzheimerin tauti (AT) on keskushermoston rappeumaan johtava sairaus, joka 
aiheuttaa yli puolet maailman dementiatapauksista. Taudin aiheuttajia ei vielä täysin 
tunneta. Sekä perintötekijät että ulkoiset tekijät, kuten elintavat ja muut sairaudet 
vaikuttavat AT-riskiin. Ulkoisten tekijöiden vaikutus saattaa johtua muutoksista 
epigeneettisissä mekanismeissa, kuten DNA:n metylaatiossa. Episodisen muistin 
heikkeneminen (EMH) aiheuttaa yleensä AT:n ensimmäiset kliiniset oireet, mutta 
sairaus pystytään diagnosoimaan vasta huomattavasti myöhemmin, jolloin hermo-
solutuho on edennyt jo pitkälle. Tarvitaan uusia menetelmiä AT:n mekanismien 
tutkimiseen sekä sairauden varhaiseen diagnosointiin. 
Tämän tutkimuksen päätavoitteina oli ottaa käyttöön uusia menetelmiä 
tautimarkkerien ja -mekanismien tutkimiseen sekä etsiä niiden avulla DNA-
metylaatiomarkkereita AT:lle sekä EMH:lle. RRBS (Reduced Representation 
Bisulfite Sequencing) otettiin ensin käyttöön tutkimalla DNA-metylaatiomuutoksia 
ihmisen alkion kantasoluissa niiden karyotyyppien muuttuessa epänormaaleiksi. 
Seuraavaksi RRBS:n avulla tunnistettiin AT:hen liittyviä metylaatiomarkkereita 
veressä suomalaisilla kaksospareilla, joista toisella on AT ja toisella ei. Markkereita 
havaittiin 11 genomin alueella. Näistä yksi, joka sijaitsi adenosine deaminase RNA 
specific B2 -geenissä (ADARB2), validoitiin ruotsalaisessa kaksosaineistossa. 
Keräsimme näytteitä uuteen kaksosaineistoon, jossa tutkimme EMH:hon liittyviä 
metylaatiomarkkereita plasman soluvapaassa DNA:ssa. Merkittäviä markkereita ei 
havaittu. Lopuksi perustimme indusoidut pluripotentit kantasolulinjat sekä aivo-
kudosmallin AT:hen liittyvien mekanismien tutkimista varten. 
Tämän tutkimuksen aikana otettiin käyttöön useita uusimpia genomin ja 
epigenomin tutkimusmenetelmiä. Keräsimme arvokkaan näyteaineiston, jota 
voidaan hyödyntää muistin heikentymisen tutkimuksessa. Tutkimuksen tulosten 
mukaan AT:hen liittyviä DNA-metylaatiomuutoksia on havaittavissa aivokudoksen 
lisäksi myös veressä. Tarvitaan kuitenkin lisätutkimuksia selvittämään, voidaanko 
metylaatiomarkkereita hyödyntää AT:n diagnostiikassa. 
AVAINSANAT: Alzheimerin tauti, tautimarkkeri, DNA-metylaatio, epigeno-
miikka, ihmisen pluripotentit kantasolut, tautimallit 
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1 Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disease that causes more than half 
of all dementia cases worldwide. For the most part, AD is a disease of the elderly, 
even though there is a more uncommon familial form of the disease that has a lower 
age of onset. Thus, the number of AD patients is increasing as people live longer and 
populations are ageing. The decline in episodic memory (EM) performance causes 
the first clinical symptoms in AD. At the moment, AD can be clinically diagnosed 
only at a very late stage, when the neurodegeneration is far-progressed and patients’ 
cognitive impairment is irreversible. In addition, most of the available therapies for 
AD only aim at alleviating the symptoms instead of stopping or even delaying the 
disease progression. There is an urgent need for new diagnostic markers for AD that 
would enable earlier detection and intervention. However, mechanisms that are 
involved in AD onset and progression are not yet completely understood, which 
hinders the development of new diagnostic and therapeutic strategies. Patient-
derived induced pluripotent stem cells (iPSC) models, which can be further 
differentiated to neural cells or 3D organoids, provide new opportunities for in vitro 
disease modelling and drug development. 
Even in the sporadic late-onset form of AD, genetic variants contribute to a major 
part of the disease risk. Genetics alone does not explain all AD cases, however, other 
external factors also have an impact on the disease risk. For example, environmental 
and lifestyle factors, as well as medical history, can either increase or decrease the 
risk and affect AD progression. According to several recent studies, this impact is at 
least partly mediated via epigenetic mechanisms, like DNA methylation. Epigenetic 
mechanisms control cellular development and function by regulating the packing of 
the genome and expression of genes without changing the nucleic acid sequence of 
the DNA. In comparison to the DNA nucleic acid sequence, epigenetic mechanisms 
are more dynamic and prone to transformation due to changes in the environment. 
The swift progression and development of new genome research tools, like next-
generation sequencing (NGS) methods, has enabled the genome-wide 
characterisation of epigenetic markers in several diseases and other biological 
conditions. Epigenetic markers not only give new insights to the molecular 
Introduction 
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mechanism of diseases but can also reveal new diagnostic marker candidates, at least 
if they can be detected in peripheral tissues that are accessible for sampling. 
The main goal of this study was to identify epigenetic markers associated with 
AD and EM impairment in peripheral blood. To reach this goal I implemented 
several methods for both genome-wide and targeted epigenetic analyses and 
characterised differences in Finnish and Swedish twin pairs discordant for the AD 
and EM impairment. Human embryonic stem cells (hESC) were utilised in the 
implementation of the genome-wide DNA methylation assay. Furthermore, another 
goal was to implement human pluripotent stem cell-derived (hPSC) AD models and 
characterise how the epigenetic markers contribute to disease progression. 
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2 Review of the Literature 
2.1 Alzheimer’s disease and dementia 
2.1.1 Dementia – a worldwide burden 
According to the World Health Organisation’s (WHO) estimation, approximately 50 
million people are suffering from dementia worldwide at the moment and close to 
10 million dementia cases are diagnosed every year. The annual costs of dementia 
to healthcare and societies in 2015 was 818 billion US dollars, which equals to 1.1% 
of the global domestic product. The greatest risk factor for dementia is old age even 
though dementia is not a normal part of ageing. As people live longer, the prevalence 
of dementia is predicted to increase, reaching 82 million by the year 2030 and 152 
million by the year 2050. Alzheimer’s disease and other dementias are the 5th most 
common cause of death. About 60-70 % of dementia cases are caused by AD. Other 
common diseases causing dementia are vascular dementia, dementia with Lewy 
bodies and frontotemporal dementias. (WHO, 2019) 
Even though there are different diseases causing dementia, the basic symptoms 
of the syndrome are relatively similar. The different disorders are characterised 
according to the pathophysiological findings that differ between diseases and are 
important for the disease progression. A common thing for dementia causing 
diseases is neurodegeneration, which leads to a typical decline in cognitive 
functions. The early symptoms start with troubles in remembering recent things 
and events and awareness of time. When the disease progresses, the patient will 
have problems surviving from everyday tasks due to periodical unawareness of 
time and place, not recognising friends and family, changes in personality and 
finally difficulties in performing basic motor functions, like walking. The patients’ 
need for external help in their daily lives increases as the disease progresses and 
symptoms become more severe. Dementia does not affect only the patients but also 
the patients’ families, caretakers and whole societies. (Alzheimer’s Association, 
2019; WHO, 2019) 
All the common diseases that cause dementia are progressive, meaning 
neurodegeneration will only worsen by time. There are specific treatment strategies 
for different diseases, however, the disease progression in all of the cases is 
Review of the Literature 
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unstoppable and any alleviation in cognitive symptoms is usually temporary. While 
there are differences in the pathophysiological processes and findings between these 
diseases, they are often very difficult to differentiate from each other in the clinics 
and mixed forms with typical findings from two or more of the diseases exist. The 
exact causes or triggers for all of the diseases remain unclear. (Alzheimer’s 
Association, 2019) 
2.1.2 Alzheimer’s disease aetiology 
The typical pathophysiological findings in the brain in AD include the 
accumulation of β-amyloid plaques inside neurons, the accumulation of tau tangles 
in the intercellular space, decreased glucose metabolism, inflammation caused by 
hyperactivated microglia, and brain tissue atrophy. Both β-amyloid and tau 
proteins have an impact on nervous system inflammation and neurodegeneration, 
however, it is not yet known what initially triggers the accumulation of these 
proteins. The changes start in brain regions that are involved in cognitive functions 
and spread to other regions along with disease progression. The pathological brain 
changes in AD may start even 20-30 years before the clinical symptoms appear 
(Villemagne et al., 2013). The brain can compensate for the neuronal cell loss and 
dysfunction at first, and major cognitive decline manifests when this capacity is 
exceeded.  
The AD progression is divided into three stages according to the patient’s 
symptoms and pathophysiological findings. In preclinical AD, the pathological 
changes have started in the brain, however, the clinical symptoms are still 
unnoticeable. In the second stage that is mild cognitive impairment (MCI) due to 
AD, the progressive cognitive decline starts to cause mild clinical symptoms, like 
memory and thinking problems, that are often noticeable at least to friends and 
family members but do not hinder everyday activities remarkably. The third stage is 
dementia due to AD. At this point, the cognitive impairment is noticeable and the 
patients start to have significant problems in surviving daily life without external 
help. (Albert et al., 2011; McKhann et al., 2011; Sperling et al., 2011) 
Genetic variants have a significant impact on AD risk and progression. A familial 
autosomal dominant form of AD exists, and it is caused by mutations in amyloid 
precursor protein (APP), presenilin 1 (PSEN1) and/or presenilin 2 (PSEN2) genes 
that are directly involved in increased accumulation of β-amyloid in the neuronal 
cells. However, the familial form accounts for only about 0.1% of all the AD cases. 
The dominant hereditary AD has a typical early age of onset usually before 65 years, 
thus, it is often called early-onset AD (EOAD). (Blennow, Leon and Zetterberg, 
2006) Genetic variance plays a significant role also in the sporadic late-onset AD 
(LOAD). According to twin and family studies, genetics may contribute up to 80 % 
Mikko Konki 
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of the attributable risk also in the sporadic forms (Wilson et al., 2011). Certain 
apolipoprotein E (APOE) genotypes, especially APOE ε4, are a well-known risk 
factor for AD, which explains up to 20 % of the risk (Genin et al., 2011). Genome-
wide association studies have identified close to 30 genomic loci contributing to the 
genetic AD risk, with varying effects, however, a large part of the genetic component 
in LOAD remains unclear (Lambert et al., 2013; Ridge et al., 2016; Jansen et al., 
2019). 
The greatest risk factor for AD is old age even though AD is not a direct 
consequence of ageing itself (Nelson et al., 2011). Alzheimer’s disease prevalence 
increases from 3 % in people aged 65-74 to 17 % in people aged 75-84 and 32 % in 
people aged 85 or more (Hebert et al., 2013). Family history is another significant 
risk factor for AD if close relatives have the disease, which may be due to both 
genetics and shared environmental conditions. External factors, some of which can 
be modulated by lifestyle choices, also affect AD risk. Cardiovascular disease and 
AD share many common risk factors, like diabetes, obesity in midlife, high 
cholesterol, hypertension and smoking (Solomon et al., 2009; Rönnemaa et al., 
2011; Rusanen et al., 2011; Gudala et al., 2013; Vagelatos and Eslick, 2013; 
Beydoun et al., 2014; Gottesman et al., 2017; Abell et al., 2018). Higher education, 
physical and social activity, cognitional engagement and a diet that promotes 
cardiovascular health have been associated with decreased risk for AD (Saczynski et 
al., 2006; Sando et al., 2008; Morris et al., 2015; Yates et al., 2016; Stephen et al., 
2017). 
2.1.3 Alzheimer’s disease diagnosis and treatment 
At the moment, clinical AD diagnosis, as well as diagnosis of other forms of 
dementia, is based on neurophysiological and cognitive testing and information 
about the individual’s family and medical history. Dementia itself is usually rather 
easy to diagnose, however, identifying the exact disease that causes the dementia is 
impossible with only these methods. Besides, dementia is usually detected at a very 
late stage, when neurodegeneration and cognitive impairment are already far 
progressed, which also decreases the efficacy of possible treatments (Villemagne et 
al., 2013). Promising biomarkers for AD diagnosis have been identified, however, 
they are not yet in standard use. 
A biomarker is a biological finding that indicates a specific condition or disease 
and can be measured reliably. In AD, the most studied biomarkers are β-amyloid 
and tau accumulation, brain tissue atrophy and decreased glucose metabolism in 
the brain. Increased amounts of tau and β-amyloid proteins can be detected in 
cerebrospinal fluid (CSF) in AD already at the early MCI stage. Also increased 
peripheral blood plasma tau level is a strong marker candidate for AD. (Olsson et 
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al., 2016) Another approach for AD biomarkers is to measure the 
pathophysiological changes directly in brain tissue via imaging. Magnetic 
resonance imaging (MRI) can be used to detect AD-associated brain atrophy, in 
other words, changes in brain tissue morphology and volume. With positron 
emission tomography (PET) it is possible to measure β-amyloid burden and 
changes in glucose metabolism in the brain. (Rathore et al., 2017) Both imaging 
and CSF/blood biomarkers for AD are already in wide use in medical and clinical 
research, however, there are still a few obstacles to overcome before they can be 
utilised in clinical diagnostics worldwide. There are no standardised methods for 
measuring CSF and blood biomarkers for AD, which means that the analysis 
results may vary between research centres. Imaging, like PET and MRI, on the 
other hand, requires very specific and expensive equipment and expertise and may 
also be too time-consuming for clinical patient screening. In addition, most of these 
biomarkers can be detected only at a quite late stage in AD pathogenesis, whereas 
early diagnosis would be preferable (El Kadmiri et al., 2018).  
All the currently approved drug treatments for AD target towards alleviating 
the symptoms of neurodegeneration. They regulate the amounts of 
neurotransmitters in synapses and enhance signal transmission between neuronal 
cells in the brain. Memantine is the only agent that can also slow down 
neurodegeneration by decreasing harmful extrasynaptic glutamatergic activity in 
some cases of moderate to severe AD (Wang and Reddy, 2017). None of the 
current treatment methods can stop the progressive neurodegeneration in AD. 
Thus, the benefits of these therapies are only temporary. In recent years, a vast 
number of clinical trials on new AD drug therapies have failed due to low treatment 
efficiency. It is difficult to find effective treatments for AD since the mechanisms 
causing the disease are still unclear and current diagnostic methods are inadequate 
for accurate AD detection. (Alzheimer’s Association, 2019) Recruiting AD 
patients in clinical trials is complex as the disease starts to progress tens of years 
before it can be diagnosed, and the most promising results may be achieved if 
treatments are started already at a very early stage of AD progression. Thus, 
predictive biomarkers for AD would be invaluable for both clinical AD research 
and clinical diagnostics. (Winblad et al., 2016) 
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2.2 Epigenetics and Alzheimer’s disease 
2.2.1 Epigenome 
The epigenome, by definition, refers to something that is “on the genome”, which is 
fitting as the epigenetic mechanisms are relatively dynamic modifications that bind 
on the DNA. Inside the cells, DNA is packed into small basic units, called 
nucleosomes, around histone proteins. The core histones include four different 
proteins; H2A, H2B, H3 and H4 that form a complex of eight histones, two of each 
subunit and bind the DNA around them. The nucleosomes, DNA and histone 
proteins, together with other non-histone chromosomal proteins form tightly 
condensed chromatin that is packed into a certain number of chromosomes. The 
number of chromosomes varies between species. Chromatin may be in more loosely 
packed euchromatin or more condensed heterochromatin forms. Heterochromatin 
usually contains only a few genes and it is especially concentrated in certain 
functional parts of the chromosomes, like centromeres and telomeres. However, the 
packing of chromatin is dynamic and can be changed from silenced tightly 
condensed to more active and loosely packed forms, and vice versa. (Alberts et al., 
2008) 
Epigenetic mechanisms regulate the activity of the genome and gene 
transcription in two ways: by locally regulating the packing of the DNA, making it 
more or less open for gene reading, or directly altering the DNA’s affinity to certain 
regulatory enzymes and other proteins that initiate or prevent transcription of the 
genes. The epigenetic mechanisms include methylation of certain nucleotides in the 
DNA, post-translational histone modifications and a variety of non-coding RNAs 
(ncRNA), as illustrated in Figure 1. All the epigenetic mechanisms are required for 
the normal functioning of cells as well as cell differentiation, development and 
division. Thus, defects in these systems often cause problems in cell homeostasis 
and may even lead to severe diseases. Epigenetic changes or distinct epigenetic 
patterns and profiles have been associated with several human diseases. In cancers, 
for example, the epigenetic changes are often genome-wide and promote cancer cell 
survival and proliferation. During the past 20 years, it has become evident that 
epigenetic mechanisms play important roles in almost all known diseases, from 
autoimmune diseases to cardiovascular problems and neurological disorders, like 
AD. (Urdinguio, Sanchez-Mut and Esteller, 2009; Brooks et al., 2010; Dorn et al., 
2019) 
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Figure 1. The epigenetic mechanisms. The basic epigenetic mechanisms include post-
translational histone modifications, DNA methylation and a variety of non-coding RNAs. 
Histone modifications (methylation, acetylation etc.) that attach to the tails of the core 
histone proteins alter the packing and activity of the genome. DNA methylation also has 
an important role in regulating the packing of the genome but it can also locally modify 
DNAs affinity towards protein complexes that are involved in gene transcription. Non-
coding RNAs regulate gene transcription by attaching to DNA or bind to mRNA products 
and control downstream processing, among various other mechanisms. 
As the epigenome is tightly intertwined with the genome, they function as a single 
unit controlling each other’s structure. Thus, genetic variation is a major cause of 
epigenetic variation between individuals and populations. Such variation can be 
seen, for example, when comparing the epigenomes of monozygotic and dizygotic 
twin pairs. Monozygotic twins share identical DNA and also their epigenomes are 
initially practically indistinguishable, whereas dizygotic twins have more 
differences in both their genomes and epigenomes. However, the epigenomes of 
DZ twins are more different also because they originate from two separate zygotes, 
whereas MZ twins originate from a single zygote. Each zygote has a unique 
epigenetic profile. (Kaminsky et al., 2009) Genetic variation may influence the 
epigenetic mechanisms in a variety of different ways. For example, genes encoding 
enzymes that regulate the epigenetic mechanisms may have different variants with 
varying efficiencies or affinities towards certain genomic regions (Potter et al., 
2013). Epigenetic profiles may be affected by genetic variation at the sites where 
a modification binds to the DNA. However, genetic variants can also have an 
impact on more distant epigenetic features within the chromosome or even in other 
chromosomes. (Ng et al., 2017) 
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The epigenetic mechanisms are both stable and dynamic. Epigenetic profiles are 
partly inheritable from cell to cell in mitotic cell division as well as from a parent to 
a child. However, epigenetic mechanisms also respond to internal and external 
stimuli, which causes changes and epigenetic variation. For example, nutrition has a 
major impact on the epigenome and it can even alter the risk for certain diseases, like 
cancers, via changes in the epigenetic mechanisms (Sapienza and Issa, 2016). Even 
though epigenetic profiles are partly heritable, a major epigenetic reprogramming 
occurs in the germline and fertilized egg cells. In this phenomenon, the epigenome 
resets to allow the cells to start to develop and differentiate into functional cells as 
parts of organs and organisms. (Heard and Martienssen, 2014) After all, cells in 
different organs and tissues have tissue-specific epigenetic profiles and gene 
expression profiles. Different cell types within an organism have very distinctive 
functions from one another, thus, they also require different genes to be active to 
fulfil their tasks. Since epigenetic mechanisms are susceptible to environmental 
changes and can also be heritable, some epigenetic changes caused by environmental 
factors can be carried through generations. However, this kind of transgenerational 
epigenetic inheritance has been mostly studied in animals whereas findings from 
human studies require further validation (Horsthemke, 2018; Perez and Lehner, 
2019). 
2.2.2 Epigenetic mechanisms 
2.2.2.1 DNA methylation 
DNA methylation means the addition of methyl groups to the base molecules of the 
nucleotides in DNA. Two of the four bases in DNA, cytosine and adenine, can be 
methylated (Wu et al., 2016). Cytosine methylation is far more common and more 
extensively studied. Methyl group binds to the fifth atom, which is carbon, in the 
six-atom ring of a cytosine. DNA methylation does not affect cytosines binding 
affinity to other bases; methylated cytosines pair with guanines the same as 
unmethylated ones in the double-stranded DNA molecule. However, DNA 
methylation regulates the packing of the chromatin and changes DNA’s affinity to 
certain DNA-binding enzymes and proteins, like transcription factors. (Alberts et al., 
2008) 
The most common form of DNA methylation is the methylation of CpG 
dinucleotides, where a methyl group is added to a cytosine that is followed by a 
guanine in the DNA sequence. However, also other cytosines can be methylated, 
which occurs especially in PSCs and brain tissue (Ziller et al., 2011; Guo et al., 
2014). The CpG sites are often concentrated on certain functional regions, like gene 
promoters and enhancers, which regulate gene activity and transcription. CpG rich 
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regions are called CpG islands, shores or shelves, depending on their location and 
distance to the nearest gene. (Alberts et al., 2008) 
At a local level, methylation of a CpG rich gene promoter usually silences the 
gene, in other words, prevents gene transcription. About 60 % of human genes have 
CpG rich promoters and most of them remain unmethylated even if the gene is 
otherwise silenced. (Weber et al., 2007; Hill et al., 2018) When a gene is silenced 
CpG rich promoter is not necessary methylated, however, repression may occur due 
to Polycomb system-mediated addition of H3K27me3 histone marks for example 
(Lynch et al., 2012). The Polycomb group family of proteins consists of Polycomp 
repressive complexes 1 and 2 that are important for regulating gene expression, 
especially during development (Moritz and Trievel, 2018). Gene bodies can also be 
relatively highly methylated, which occurs especially in highly transcribed genes in 
mammals, indicating that gene-body DNA methylation does not prevent 
transcription (Zemach et al., 2010). DNA methylation is tissue-specific; however, 
only about 20 % of the detected CpG sites in the human genome are differentially 
methylated between normal tissues. These dynamic methylation differences that 
occur during development are associated with genomic regions that have tissue-
specific functions, for example, genes that are expressed only in specific tissues. 
(Ziller et al., 2013; Schultz et al., 2015) 
On a more widespread level, DNA methylation plays an important role in 
genomic imprinting and permanent repression of transposable elements. In genomic 
imprinting, DNA methylation, in cooperation with histone modifications and non-
coding RNAs, can condense and silence large genomic regions or even whole 
chromosomes (Delaval et al., 2007; Ideraabdullah, Vigneau and Bartolomei, 2008). 
The inflicted genes are thus expressed only from one of the two alleles found in 
diploid genomes. The human genome, for example, is diploid meaning that there are 
two copies, i.e. alleles, of each gene. One copy is inherited from the mother and the 
other from the father. Transposable elements are DNA sequences of varying lengths 
that can move in the genome. While activated, they decrease the genomic stability 
and can cause different kinds of mutations. They offer an important platform for 
evolutionary development; however, mutations can often be harmful to the 
organism. Most of the genomic regions containing transposable elements are heavily 
methylated, which keeps them inactive. (Bourque et al., 2018) 
Three active DNA methyltransferase enzymes, DNMT1, DNMT3A and 
DNMT3B, exist in human cells and catalyse the addition of methyl groups into 
cytosines in DNA. DNA methylation patterns can be inherited in both mitotic and 
meiotic cell division, where DNMT1 is responsible for copying the pattern to the 
replicated DNA strand. The other two enzymes, DNMT3A and DNMT3B, can add 
methyl groups later and alter the cells' responses to different external and internal 
stimuli. The methyl groups attached to cytosine nucleotides can also be converted to 
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hydroxymethyl groups. Ten Eleven Translocation (TET) family proteins, TET1, 
TET2 and TET3, can oxidate the methyl group. This reaction is crucial for active 
demethylation of the cytosines and it is required in many basic biological processes, 
like cell differentiation. (Rasmussen and Helin, 2016) 
2.2.2.2 Histone modifications 
Post-translational histone modifications are small molecule groups that are 
covalently added to the histone proteins. Histones have N-terminal amino acid side 
chains pointing out from the nucleosome. Modifications are usually attached into 
specific amino acids in these side chains, however, there can also be modifications 
closer to the nucleosomes core. Common post-translational modifications of histone 
side chains are mono-, di- and trimethylation of lysines and arginines, acetylation of 
lysines, phosphorylation of serines, threonines and tyrosines, and ubiquitylation and 
sumoylation of lysines. (Bannister and Kouzarides, 2011) 
The histone modifications are usually dynamic and different enzymes mediate 
the addition and cleavage of the small molecules to and from the histone tails. For 
example, histone acetyltransferases, also known as HATs, add acetyl groups to 
lysines, whereas histone deacetylases, i.e. HDACs, cleave them off. (Grunstein, 
1997) The modifications occur usually in only certain amino acids in the histones’ 
side chains and have specific roles in chromatin functions and activation or 
inactivation of genomic regions. Acetylation of lysines in the histones side chain, for 
example, histone three lysine nine (H3K9ac), is usually a mark for active chromatin 
(Koch et al., 2007), whereas methylation can be associated with either active or 
repressed chromatin, depending on the location and level of methylation. For 
example, monomethylation of histone three lysine nine (H3K9me) is found on active 
chromatin, and trimethylation of the same amino acid (H3K9me3) is associated with 
repressed chromatin. (Barski et al., 2007) 
Combining histone modification data from Chromatin Immunoprecipitation and 
Sequencing (ChIP-seq) with information about transcription factor binding sites and 
chromatin accessibility has been crucial in identifying histone modification 
combinations that mark different activity states of the chromatin. For example, 
H3K4me1 together with H3K27ac mark active gene enhancers, the combination of 
H3K4me1, H3K4me2 and a high ratio of H3K4me3 marks active promoters and 
H3K36me3 together with high RNA polymerase II activity indicate actively 
transcribed genome regions (Jiang and Mortazavi, 2018). With this information, it is 
possible to detect new regulatory regions in the genome. 
There are a relatively low number of reports on specific histone modification 
alterations in other human diseases than cancers. This is partly because DNA 
methylation has been easier to study, which is why many groups focus on that rather 
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than histone modifications. Histone modifications are more dynamic than DNA 
methylation, thus, there may not be many stable histone markers in other human 
diseases, whereas in cancers the entire genetic and epigenetic regulation is harnessed 
to ensure survival and proliferation of the cancer cells. HDAC inhibitors have been 
approved for clinical treatment of certain lymphomas. (Jones, Issa and Baylin, 2016; 
T. Muka et al., 2016; Taulant Muka et al., 2016; Wen et al., 2016) However, as 
histone modifications are important in regulating gene expression, characterising 
disease-specific histone profiles can reveal new insights to disease mechanisms and 
even new therapeutic targets in the future. 
2.2.2.3 Non-coding RNAs 
Non-coding RNAs are transcribed from the genome, however, instead of being 
translated into proteins they remain as RNAs and regulate the activity of the genome 
and gene expression via several different mechanisms. ncRNAs can, for example, 
impact the packing of the chromatin by regulating local DNA methylation and 
histone modifications, affect gene transcription by regulating enhancer-promoter 
interactions or control the levels of messenger RNAs transcribed from different 
genes (Rothschild and Basu, 2017; Ransohoff, Wei and Khavari, 2018). The length 
of the ncRNAs varies from 22 nucleotide-long microRNAs to more than 200 
nucleotide-long long non-coding RNA (lncRNAs) and 5070 nucleotide-long 28S 
ribosomal RNA and everything in between. Non-coding RNAs are categorized into 
different groups according to their length and function in the cells. (Mattick and 
Makunin, 2006) 
There are at least ten different RNA species categorised. Some of them, like 
transfer RNA (tRNA) and ribosomal RNA (rRNA) have already been detected tens 
of years ago, however, the number of known ncRNAs has been growing quickly 
during the recent years. The total number of ncRNAs is still unknown and new 
molecules are detected at a fast rate due to development in genome sequencing and 
data mining tools. (Sharp et al., 1985; Lafontaine and Tollervey, 2001; Uszczynska-
Ratajczak et al., 2018) Non-coding RNAs are important in regulating normal 
development and function of the cells and organisms. Defects in ncRNA networks 
and functions have been detected in several human diseases, especially in cancers 
but also in AD (Millan, 2017; Anastasiadou, Jacob and Slack, 2018). 
2.2.3 Epigenome and environment 
The environment starts to modify the epigenome already before birth. The mother’s 
diet and lifestyle have a significant impact on the developing offspring’s epigenome. 
The epigenome of the offspring during pregnancy is especially vulnerable due to the 
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epigenetic reprogramming and high cell division rate. How the prenatal environment 
and stress can impact epigenome has been studied in animal models for a large part, 
however, there is some evidence from human studies as well. A classic example of 
such stress-induced impact on the epigenome in humans is the Dutch famine study 
that inspected the effect of inadequate maternal nutrition, during winter 1944-45, to 
foetal growth and the progeny’s increased risk for several diseases in later life 
(Lumey, 1992; Roseboom, de Rooij and Painter, 2006). High-fat diet during 
pregnancy alters the expression of leptin and adiponectin genes in the offspring via 
epigenetic changes. These changes induce metabolic syndrome-like symptoms that 
persist in the mice for several generations even if the diet of the offspring is 
normalised. (Milagro et al., 2009; Masuyama and Hiramatsu, 2012; Masuyama et 
al., 2015). Inadequate nutrition of pregnant rats and mice also alters epigenetic 
profiles in glucocorticoid receptor genes of young and adult offspring (Lillycrop et 
al., 2005; Burdge et al., 2007).  
Prenatal maternal stress and exposure to synthetic glucocorticoids, which are 
often used to model stress reactions in animals, have also been linked to distinctive 
epigenetic patterns in the offspring and even elevated risk for certain diseases and 
medical conditions during later life (Mueller and Bale, 2008; Oberlander et al., 2008; 
Crudo et al., 2013). Prenatal environment and maternal stress have a significant 
impact on nervous system development as well as immune and cardiovascular 
system functions and metabolism of the offspring (Cao-Lei et al., 2016). In addition 
to maternal stress and diet, also certain behaviour, like the quality of maternal care 
over an infant or childhood abuse, and toxins can cause changes in the offspring’s 
epigenome in both humans and animals (McGowan et al., 2009, 2011; Faulk and 
Dolinoy, 2011). 
Even though the epigenome in later life is not as susceptible to external stimuli 
as during prenatal development, the environment and lifestyle factors continue to 
modify the epigenome throughout adult life. Furthermore, in later life, the epigenetic 
changes usually occur in a subset of already differentiated cells, whereas during 
prenatal development all cells in the embryo/foetus may be affected. Genome-wide 
changes in histone H3 methylation have been linked to obesity and type 2 diabetes 
in adults (Jufvas et al., 2013). Caloric restriction can hinder age-related DNA 
methylation changes in the adult mouse hippocampus (Chouliaras et al., 2012). High 
caloric diet impacts DNA methylation also in human muscle cells (Jacobsen et al., 
2012). Global methylation levels in the repetitive DNA regions decrease during 
ageing of the individual, which is probably due to reduced DNMT1 activity (Casillas 
et al., 2003; Bollati et al., 2009). A healthy diet and physical activity have been 
linked to decreased risk for several cardiovascular, metabolic and 
neurophysiological diseases, which is most likely mediated by epigenetic 
mechanisms that alter the gene expression in all tissues (Kaliman et al., 2011) 
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Exposure to toxic compounds can cause epigenetic changes. For example, tobacco 
use has a long-lasting genome-wide impact on DNA methylation profile, which can 
be detected even in peripheral blood (Breitling et al., 2011). Alcohol can also induce 
increased histone acetylation in the brain of pregnant mice and the gestating foetuses 
(Mews et al., 2019). 
2.2.4 Epigenetic alterations in Alzheimer’s disease 
Genetic factors explain a large part of the LOAD risk, however, the mere existence 
of monozygotic twin pairs discordant for AD proves that also other factors contribute 
to the disease risk. These external factors, for example, diet, physical cognitive and 
social activity, medical history and lifestyle choices may cause specific changes in 
the epigenetic mechanisms that are involved in AD pathogenesis. The epigenetic 
mechanisms are important for cognitive functions, like memory formation and 
learning, and specific epigenetic changes occur in the brain during ageing (Zovkic, 
Guzman-Karlsson and Sweatt, 2013; Sen et al., 2016) 
Many recent studies have already discovered specific epigenetic changes 
associated with AD in brain tissue and there are also a few reports about AD-associated 
DNA methylation marks in peripheral blood. However, the findings on peripheral 
blood DNA methylation markers for dementia and AD have been inconsistent due to 
limitations in the study designs, like low power or too challenging case-control 
comparisons. (Fransquet et al., 2018) DNA methylation marks associated with AD 
have been analysed in different brain regions. Table 1 puts together differentially 
methylated genes that have been associated with AD to date. All the previous genome-
wide DNA methylation analyses have been conducted with microarrays that detect 
methylation only at a predetermined set of CpG sites. In the targeted DNA methylation 
analyses, bisulphite pyrosequencing has been the most common method. While many 
of the differentially methylated genes have unknown functions and contribution to AD 
pathogenesis, some genes have known roles in nervous system functions. The wide 
range of findings from these studies shows that AD is a complex disease also from the 
epigenetics’ point of view. However, AD-associated differential methylation in some 
of the genes, for example, ankyrin 1 (ANK1), WD repeat domain 81 (WDR81) and 
homeobox A3 (HOXA3), has been confirmed by several independent research groups, 
indicating that these genes are most likely involved in the disease process (De Jager et 
al., 2014; Lunnon et al., 2014; Semick et al., 2019; Smith, Smith, Burrage, et al., 2019; 
Smith, Smith, Pishva, et al., 2019).  
At first, the studies on DNA methylation perturbations in AD focused on the key 
genes amyloid-beta precursor protein (APP), PSEN1 and microtubulin associated 
protein tau (MAPT) that are known to be important in the pathogenesis according to 
previous studies. Even though small-scale studies reported interesting findings of 
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distinctive DNA methylation patterns in for example APP gene, these findings could 
not be confirmed in a larger cohort (West, Lee and Maroun, 1995; Barrachina and 
Ferrer, 2009). Some groups have also detected differences in global genome-wide 
methylation levels in different brain regions in AD. However, findings from different 
groups have been inconsistent: some report decreased and others increased global 
methylation or hydroxymethylation in the brain (Mastroeni et al., 2010; Chouliaras, 
Mastroeni, et al., 2013; Coppieters et al., 2014). This indicates that the possible brain 
DNA methylation changes in AD are relatively small and most likely are restricted 
into specific short genomic regions. 
Alzheimer’s disease-associated changes in histone modifications have been 
remarkably less studied than DNA methylation. DNA methylation is easier to 
quantify than histone markers, at least for now, and histones are not as stable as 
DNA methylation during processing and storage of the post-mortem brain tissue 
samples that the AD research material often consists of. Some groups have reported 
that HDAC inhibitors may have a protective role against AD and cognitive 
impairment and the basic HDAC levels increase by age in human and mice brain 
(Fischer et al., 2007; Gräff et al., 2012; Ricobaraza et al., 2012; Chouliaras, van 
den Hove, et al., 2013; Rumbaugh et al., 2015). Gjoneska and her group (2015) 
studied post-translational histone marks in an AD mouse model and reported an 
increase in active chromatin marks H3K27ac and H3K4me3 associated with genes 
involved in immune responses. In recent years, many groups have reported 
differences in ncRNAs in AD. Changes in ncRNA functions and expression levels 
have been associated with the pathophysiological molecular and cellular changes 
in AD, even though their actual contribution to the disease outcome is still unclear. 
(Millan, 2017) 
There is growing evidence that epigenetic mechanisms play an important role in 
AD pathogenesis. The major limitation of the studies on the epigenetic changes in 
AD so far is that the analysis of human post-mortem brain tissue samples cannot 
reveal whether epigenetic alterations are a cause or a consequence of the disease and 
at which point of the disease progression they appear. Animal models are valuable 
for studying longitudinal changes associated with diseases, however, the 
mechanisms between human diseases and animal disease models are not necessarily 
identical. Besides, the most commonly used AD animal models rely on inducing AD-
like pathological changes in animals’ nervous system via mutations in genes that 
have been associated with the disease, like APP, MATP1 or PSEN1. Thus, they are 
better at modelling familiar AD instead of the sporadic disease that contributes to 
more than 90 % of the cases in humans. (Götz, Bodea and Goedert, 2018; Zhang et 
al., 2020) Another possibility is to study epigenetic alterations in hPSC models, 
which enable the analysis of longitudinal epigenetic changes in human tissues during 
neuronal cell development and even different stages of neurodegeneration. 
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Table 1. Genes located closest to differentially methylated genomic regions in Alzheimer’s disease. 
Genes Tissue Analysis 
method 
Study/ 
reference 
S100A2 Frontal cortex MethyLight PCR (Siegmund et al., 2007) 
BDNF, COX2, CREB, 
NFKB, SYP 
Frontal cortex MSRE-PCR (Rao et al., 2012) 
TMEM59 Frontal cortex Microarray (Bakulski et al., 2012) 
SORBS3 Entorhinal, temporal 
and prefrontal cortex 
Frontal cortex 
Microarray, 
pyrosequencing 
MethyLight PCR 
(Sanchez-Mut et al., 2013) 
(Siegmund et al., 2007) 
SPTBN4 
TBXA2R 
Frontal cortex Microarray, 
pyrosequencing 
(Sanchez-Mut et al., 2013) 
DUSP22 
IGFBP7 
Hippocampus Microarray, 
pyrosequencing 
(Sanchez-Mut et al., 2014) 
ANK1 Entorhinal, temporal 
and prefrontal cortex 
Microarray, 
pyrosequencing 
(Lunnon et al., 2014) 
ANK1, BIN1, CDH3, 
FOXK1, HMHA1/ABCA7, 
HOXA3, KDM2B, ITPRIPL2, 
PCNT/DIP2, RHBDF2, 
SLC2A1, SPG7/RPL13, 
WDR81/SERPINF1/SERPI
NF2 
Entorhinal, temporal 
and prefrontal cortex 
Microarray (De Jager et al., 2014) 
TREM2 Superior temporal 
gyrus 
Microarray, 
pyrosequencing 
(Smith et al., 2016) 
NCAPH2/LMF2 Peripheral blood Microarray, 
pyrosequencing 
(Kobayashi et al., 2016) 
NCAPH2/LMF2 Peripheral blood 
leukocytes 
Pyrosequencing (Shinagawa et al., 2016) 
MOV10L1, B3GALT4, 
DUSP6, TBX15, HLA-
J/ZNRD1-AS1, PRDM16, 
ELOVL1, RIBC2/SMC1B, 
KLK7, TRIM6, FBRSL1, 
AGPAT1/RNF5/RNF5P1, 
VAX2, PPT2/PPT2-
EGFL8/PRRT1, 
C10orf105/CDH23, KIF25, 
NRG2, RNF39, CMYA5, 
TNXB, NAV2, TAP2, 
ZNF177/ZNF559-ZNF177, 
FLOT1/IER3 
Superior temporal 
gyrus 
Microarray (Watson et al., 2016) 
BMAL1 Frontal cortex Microarray (Cronin et al., 2017) 
HOXA cluster Prefrontal cortex and 
superior temporal 
gyrus 
Microarray (Smith et al., 2018) 
MCF2L, ANK1, MAP2, 
LRRC8B, STK32C, 
S100B, HOXA3, APP, 
ADAM17 
Frontal and temporal 
cortex, separated 
neurons and glial 
cells 
Microarray (Gasparoni et al., 2018) 
ANK1, WNT5B, FBXL16, 
ALLC, ARID5B 
Entorhinal cortex Microarray (Smith, Smith, Pishva, et 
al., 2019) 
ANK1 Entorhinal cortex, 
superior temporal 
gyrus, cerebellum 
Pyrosequencing (Smith, Smith, Burrage, et 
al., 2019) 
ANKRD30B, 
WDR81/SERPINF1/SERP
INF2, ANK1, DUSP22, 
JRK, NAPRT, CSNK1G2 
Prefrontal cortex, 
entorhinal cortex, 
hippocampus 
Microarray (Semick et al., 2019) 
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2.2.5 Twin studies – a unique perspective into epigenetic 
variation 
Monozygotic (MZ) twins have identical genomes and yet there are phenotypic 
differences between the twins. The epigenetic profiles of MZ twins are practically 
indistinguishable at first and start to deviate from one another only by time. (Fraga 
et al., 2005) Monozygotic twins are of same-sex and age and are usually exposed to 
the same environmental factors before birth and during early life. However, 
differences in environment and lifestyle in later life together with pure stochastic 
variation introduce deviation to their epigenetic profiles, phenotypes and risk for 
certain diseases as well. Dizygotic (DZ) twins share on average 50 % of the same 
genetic pool and have similar living environments during early life. As genetic and 
epigenetic features are intertwined, the epigenetic variation between individuals is 
for a large part determined by genetic differences. Thus, twin studies are beyond 
comparison when characterising epigenetic differences that occur by time and 
contribute to different phenotypic profiles. 
Twin studies can be utilised in studying how somatic mutations induce 
epigenetic changes and analysing epigenetic differences between twin pairs 
discordant for certain trait or disease gives unique information about the epigenetic 
mechanisms’ and external factors’ contribution to the trait or disease of interest. 
(Kim et al., 2016) Power estimation of an epigenome-wide association study using 
samples from discordant twin pairs has demonstrated the unbeatable sensitivity of a 
twin study design in comparison to basic case-control design. To reach certain 
power, a traditional case-control study may require up to ten times more samples 
than a disease-discordant twin study. However, the number of samples required is 
also dependent on the desired power level as well as the heredity of the disease of 
interest among other factors. (Li et al., 2018) Furthermore, the scarce number of 
existing twin sample cohorts is probably the most significant limiting factor for the 
usage of this kind of study designs in epigenetic research. 
2.3 Unravelling the epigenome – DNA methylation 
analysis via bisulphite sequencing 
2.3.1 Genome-wide DNA methylation analysis 
As DNA methylation is by far the most studied epigenetic mechanism, several 
different methods have been developed for DNA methylation analysis. All the 
methods have certain advances and limitations in comparison to each other, which 
makes all of them important for epigenetic research. Genome-wide analysis methods 
are very popular in discovering novel DNA methylation markers for diseases and 
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other conditions, whereas targeted methods are often utilised in validating these 
markers. The most popular methods quantify methylation at single-nucleotide 
resolution, i.e. at each methylation site, however, some methods that quantify 
methylation on larger regions are also utilised in some cases. (Bock et al., 2010; 
Kurdyukov and Bullock, 2016) 
The most commonly used genome-wide methods are bisulphite sequencing and 
methylation-sensitive bead microarrays. Both of these methods detect methylation 
at single-nucleotide resolution. The latest version of Illumina microarrays can 
quantify methylation at up to 850,000 of the 28 million CpG sites found in the 
human genome. These predetermined CpG sites are located in promoters and other 
functionally interesting regulatory regions of the genome. Microarrays provide 
highly reproducible data at low costs and the data analysis is standardised and 
straightforward. However, microarrays often cover only a few methylation sites in 
a specific regulatory region, which can give biased information on the whole 
region’s methylation level. In addition, it is not possible to discover new 
methylation markers with microarrays as they target only specific methylation 
sites. (Pidsley et al., 2016) Whole-genome bisulphite sequencing (WGBS) can 
detect methylation at each of the 28 million CpG sites found in the human genome, 
in principle. In practice, however, analysing all CpG sites with adequate certainty 
would increase the sequencing costs a great deal, making it usually more sensible 
to increase the number of samples instead of deeper sequencing. WGBS also 
produces vast amounts of data, which complicates data management and analysis. 
(Ziller et al., 2015) 
There are also other methods for genome-wide DNA methylation analysis that 
rely on chromatography and/or mass spectrometry or enzyme-linked immunosorbent 
assay (ELISA). These methods have lower resolution than bisulphite sequencing or 
microarrays as they quantify mean methylation in larger DNA regions rather than 
single nucleotides. Since there are commonly used protocols and even commercial 
kits for these methodologies, they can still be utilised to study changes in global 
whole-genome methylation levels when cultured cells are treated with agents that 
impact DNA methylation or demethylation on a large scale. (Kurdyukov and 
Bullock, 2016) 
2.3.2 Bisulphite sequencing 
DNA methylation analysis via bisulphite sequencing is based on two important steps: 
bisulphite conversion, where the unmethylated cytosines in DNA are chemically 
converted into uracils, and sequencing, where the base sequence of the genome or 
the region of interest is characterised. In bisulphite conversion, only unmethylated 
cytosines react with the conversion reagent, whereas the methyl group protects 
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methylated cytosines (Frommer et al., 1992). Hydroxymethyl also protects the 
cytosine nucleotide from bisulphite conversion reagent similar to the methyl group. 
Thus, it is not possible to distinguish methylated and hydroxymethylated cytosines 
from each other with bisulphite sequencing. Converted uracils are replaced with 
thymines when the samples are amplified in polymerase chain reactions (PCR). 
When the DNA base sequence in the sample is sequenced, the methylation per cent 
of a CpG site can be calculated from the relative amount of cytosines and thymines 
detected in any specific location. 
Bisulphite conversion is utilised in both genome-wide and targeted DNA 
methylation analyses. In targeted DNA methylation analysis a short genomic region 
of interest is amplified in PCR with target-specific primers after bisulphite 
conversion of the genomic DNA, and methylation levels are quantified via 
pyrosequencing, for example. (Bassil, Huang and Murphy, 2013) In genome-wide 
bisulphite sequencing, the whole genomic DNA is usually PCR amplified after 
conversion and the nucleic acid sequence is analysed with a high-throughput 
sequencing platform, like Illumina HiSeq or NovaSeq. Some protocols do not require 
PCR amplification since PCR can introduce bias in the methylation results (Olova et 
al., 2018). In comparison to the DNA methylation-sensitive microarrays, the greatest 
strength of bisulphite sequencing is that it can detect new methylation sites, whereas 
microarrays target only a limited number of sites that are already known (Kurdyukov 
and Bullock, 2016). 
WGBS produces vast amounts of data, especially if the number of samples is 
large. Only 2 % of the human genome encodes proteins and for a large part, the 
function of the non-coding genome remains unknown. Thus, analysing the whole 
genomes from large sample sets produces huge amounts of data that is difficult to 
store and analyse, while most of the information comes from the unknown non-
coding regions or may not have any methylation sites. Sequencing of WGBS 
libraries is also still quite expensive. Reduced Representation Bisulfite Sequencing 
(RRBS) was developed to analyse the CpG rich regions of the genome, like gene 
promoters. The RRBS workflow, including sequencing library preparation and 
data analysis, is illustrated in Figure 2. It utilises a restriction digestion enzyme, 
MspI, which cuts the DNA between the two cytosine nucleotides in CCGG 
sequence sites. Thus, each DNA fragment in the sequencing library sample 
contains methylation information from at least one CpG site. The digested DNA 
fragments are size selected and amplified during the library preparation, which 
increases the amount of CpG rich DNA in the sample. More CpG rich regions in 
the library sample mean that after sequencing there will be more data from the 
coding regions and promoters that regulate gene expression. In comparison to 
WGBS, sequencing of RRBS libraries is less expensive, and the datasets are a lot 
easier to handle, which is why RRBS is frequently used even though the sequence 
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information from large parts of the genome is lost. (Meissner et al., 2005; Boyle et 
al., 2012) 
 
Figure 2. Reduced Representation Bisulfite Sequencing workflow. 
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2.3.3 Bisulphite sequencing data analysis 
After sequencing the RRBS or WGBS libraries, the next step is data analysis. The 
same as with all high-throughput sequencing experiments, bisulphite sequencing 
data analysis starts with sequencing read quality checking and trimming and 
discarding low quality reads. Sequencing read is the nucleotide sequence of a 
single DNA fragment in the library sample. The pre-processed reads are then 
aligned and mapped to a reference genome. Bisulphite sequencing data requires a 
specific mapping software, for example, Bismark, since the DNA has been 
bisulphite treated and all unmethylated cytosines are converted to thymines and 
DNA sequence complexity is reduced. Bisulphite conversion efficiency is 
controlled by adding unmethylated lambda DNA to all library samples. The 
mapping software also goes through methylation calling, i.e. quantifies 
methylation in each methylation site, and outputs the methylation data, including 
at least the sites’ location coordinates in the genome, methylation values, and 
sequencing coverages. Sequencing coverage is the number of reads covering a 
single site of interest, or in other words, how many times a specific site was 
sequenced from the library sample. (Krueger and Andrews, 2011) 
The methylation data is then exported to a differential methylation analysis 
software. There is a wide variety of software available for genome-wide bisulphite 
sequencing data analysis, for example, methylKit, RnBeads, RadMeth and dmrseq 
(Akalin et al., 2012; Dolzhenko and Smith, 2014; Korthauer et al., 2019; Müller et 
al., 2019). Bisulphite sequencing data analysis is not yet standardised and new 
methods are being developed all the time. The differential methylation analysis 
software packages differ from one another in how they handle the data. Some have 
been developed for small sample sets whereas others are optimised for tens or even 
hundreds of samples. Some programmes calculate methylation differences in 
individual sites and others focus on regional methylation differences. The most 
important difference between the programmes is, how they measure the significance 
of the differentially methylated sites and correct the results for multiple testing error. 
The statistical model each software uses also sets the limit to the number of 
confounding factors that can be included in the analysis. Thus, it is important to 
consider and test different analysis methods, which is the most suitable for specific 
data set and experimental design. (Akalin et al., 2012; Song et al., 2013; Korthauer 
et al., 2019; Müller et al., 2019) 
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2.4 Human pluripotent stem cells in disease 
modelling 
2.4.1 Human pluripotent stem cells 
Human pluripotent stem cells are an invaluable resource for regenerative medicine 
and disease modelling. Pluripotent stem cells have two defining characteristics: in 
theory, they can differentiate into all cell types and tissues found in the body, and 
they can proliferate indefinitely. There are two types of human pluripotent stem cells; 
embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Embryonic 
stem cells are collected from the inner cell mass of an embryo before implantation 
in the uterus (Thomson, 1998). Induced pluripotent stem cells, on the other hand, are 
reprogrammed from differentiated somatic cells in vitro and returned to the 
pluripotent state (Takahashi et al., 2007). 
Pluripotent stem cells are already widely used to model the development of 
biological systems and diseases. Due to their ability to proliferate, PSCs can be 
cultured in vitro, and pluripotency enables the cells to be differentiated into any of 
the cell types found in the adult human body. Simpler model systems, like two-
dimensional cultures of single-cell types differentiated from stem cells, have been 
around for over ten years. With more recently invented three dimensional (3D) stem 
cell-derived organoid cultures it is also possible to study the development of larger 
biological systems. For example, with cerebral organoids, it is possible to model the 
development and function of early human brain (Lancaster et al., 2013; Lancaster 
and Knoblich, 2014). 
A common feature for all stem cell applications is that the cells must be cultured 
in vitro in laboratory conditions. During culturing, the stem cell colonies are 
expanded to ensure enough cells for the application and passaged to provide the best 
environment for cell proliferation and to prevent spontaneous differentiation of the 
cells. However, prolonged in vitro culturing also provokes genetic and epigenetic 
changes in the PSCs. These changes may alter the behaviour of the cells by affecting 
their ability to differentiate and proliferate and compromise their suitability for 
research use. (Lund, Närvä and Lahesmaa, 2012) 
2.4.2 Human pluripotent stem cell cultures and genomic 
stability 
While PSCs can be maintained in in vitro cultures for tens of passages, in vivo they 
usually exist only transiently. Thus, the PSCs’ ability to proliferate indefinitely is 
artificial and only seen in laboratory cultures. Prolonged culturing of PSCs has 
revealed a significant vulnerability in these cells as epigenetic reprogramming 
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exposes their genome to changes. (Heard and Martienssen, 2014; Weissbein, 
Benvenisty and Ben-David, 2014) Genomic aberrations occur on many levels in 
PSCs during in vitro culturing. Large karyotypic changes, e.g. the gain of 
chromosomes 12 and 17q, in ESC lines were reported as early as 2004 (Draper et 
al., 2004). Additional large-scale amplifications have been detected in other 
chromosomes as well. The incidence rate that these changes occur seems to be 
similar both in ESC and iPSC lines at under 13 % of all lines. (Taapken et al., 2011) 
An increased amount of smaller-scale copy number variations (CNVs) and single 
nucleotide polymorphisms (SNPs) have been detected in PSC lines as well. 
Interestingly, increased genetic variation has also been detected in genes that can 
have an impact on the cells’ pluripotency and survivability, like BCL2 like 1 
(BCL2L1), isopentenyl-diphosphate delta isomerase 1 (IDI1), Nanog homeobox 
pseudogene 1 (NANOGP1) and DNMT3B. (Chin et al., 2009; Närvä et al., 2010; 
Laurent et al., 2011; Martins-Taylor et al., 2011) The number of focal CNV is higher 
in iPSC lines than ESCs or somatic cells, which may be due to the reprogramming 
process or selection of somatic cells that were initially reprogrammed to iPSCs 
(Laurent et al., 2011; Ji et al., 2012; Young et al., 2012). 
A wide variety of epigenetic alterations have been detected in PSC lines in vitro 
as well. DNA methylation variation is seen on both protein-coding and non-coding 
regions. Local epigenetic aberrations may lead to changes in gene expression, 
whereas widespread deviations can cause loss of gene imprinting and even partial 
reactivation of an inactivated X chromosome (Enver et al., 2005; Nazor et al., 2012; 
Bar et al., 2017; Weissbein et al., 2017). The iPSCs’ DNA methylation profile differs 
from ESCs’ during early passages in vitro, however, the differences usually diminish 
at later passages. This variation may be caused by the reprogramming process or 
imperfect epigenetic reset from somatic cells to pluripotency. (Nishino et al., 2011) 
Culturing conditions, like culturing media or oxygen level, may also cause changes 
to the epigenome (Allegrucci et al., 2007; Nazor et al., 2012). Genetic and epigenetic 
variance enables normal cells to react to external stimuli and alter their behaviour to 
survive and maintain the required functions. When the rate of these variations 
increases, the genetic and epigenetic profiles of PSCs start to resemble cancer cells 
(Harrison, Baker and Andrews, 2007; Yang et al., 2008). When transplanted to mice, 
karyotypically abnormal human ESCs have elevated tumorigenic potential 
(Werbowetski-Ogilvie et al., 2009). In a more recent study, Weissbein and his group 
(2019) identified intracellular signalling pathways, like Ras protein, Rho/Rho-
associated coiled-coil containing protein kinase (Rho-ROCK), phosphatidylinositol-
3-kinase/protein kinase B (PI3K-AKT) and Hippo, which influence the PCSs’ 
survivability and tumorigenic potential in prolonged in vitro culture. 
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2.4.3 Human pluripotent stem cell models for Alzheimer’s 
disease 
Human pluripotent stem cell models offer new perspectives for studying chronic 
progressive neurodegenerative diseases like AD. Most of the pathophysiological 
changes in AD occur in the brain. Thus, it has been difficult to study the disease 
progression in human tissues, as only post-mortem samples have been available. 
With iPSC technologies, it is possible to produce neuronal cell lines and 3D tissues 
derived from AD patients and healthy individuals and compare cell and tissue 
development between the models. Stem cell-derived disease models have been 
widely used to study neurodegenerative disorders, like AD, Huntington’s disease, 
amyotrophic lateral sclerosis and Parkinson’s disease (Centeno, Cimarosti and 
Bithell, 2018). While the 3D organoid cultures are at the moment used to study organ 
development and patient-specific disease models, in the future they may enable 
building replacement tissues for therapeutic use (Madeline A. Lancaster and 
Knoblich, 2014). 
The patient-derived disease models give new insights into the molecular and 
cellular disease mechanisms. Pluripotent stem cells have been utilised in a few AD 
studies already. In one of the earliest reports on the field, by Israel and his group 
(2012), iPSC derived neurons from familial and sporadic AD patients showed 
impaired β-amyloid and tau protein processing in comparison to controls. 
Alzheimer’s disease-associated molecular disturbances have been detected in 
neuronal cells differentiated from AD patient-derived iPSCs (AD-iPSC) in other 
studies as well, even though most of them have focused on familial AD (Yagi et al., 
2011; Muratore et al., 2014; Hossini et al., 2015; Yang et al., 2016). Also, 3D 
neuronal cell and tissue cultures differentiated from AD-iPSC have been detected to 
express phenotypes typical for AD, like the accumulation of β-amyloid and tau (Lee 
et al., 2016; Raja et al., 2016; Gonzalez et al., 2018). 
2.5 Summary 
Alzheimer’s disease is one of the most important healthcare problems in the modern 
world. Despite extensive research, the factors leading to AD are not yet completely 
known and the tools for clinical AD diagnosis and treatment are inadequate. At the 
moment, AD can be clinically diagnosed at a very late stage, even 20-30 years after 
disease progression has started. At this point, current treatment methods can only 
alleviate the clinical symptoms temporarily before the patient’s cognition starts to 
decline again. New methods that can detect AD at an earlier time point are needed 
urgently. If AD is diagnosed already at an early stage, the disease progression could 
be hindered or even stopped before major neurodegeneration has occurred and 
nervous tissue’s regenerative capability has been depleted. 
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The swift development of the latest genome and epigenome analysis methods as 
well as modern stem cell technologies have enabled the detection of new markers 
for different biological conditions and diseases, like AD. Genetic variants contribute 
to a large part of the AD risk, however, the genetic risk factors alone do not determine 
an individual’s AD risk profile. Epigenetic mechanisms, which regulate packing and 
activity of the genome, are also involved in the disease pathogenesis. As the 
pathological changes in AD appear mostly in the central nervous system during a 
time-span of several years, tracking the disease progression in the target tissues has 
been challenging. Epigenetic markers associated with AD have been identified in 
post-mortem brain tissue samples. These are invaluable findings and give new 
insights to the disease mechanisms, however, a biomarker for clinical AD diagnosis 
has to detectable in peripheral tissues, like blood, that can be sampled. Modern stem 
cell technologies, for example, patient-derived iPSC disease models, offer 
completely new possibilities for studying disease mechanisms in human cells and 
tissues. These models can also be utilised in biomarker research to validate how the 
markers are involved in the disease mechanisms within the target tissues. 
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3 Aims of the Study 
The main goal of this study was to identify and evaluate peripheral blood DNA 
methylation markers that indicate or even predict AD progression. To achieve this 
goal several methods for genome and epigenome analysis were optimised and 
implemented. The specific goals for the subprojects were: 
1. To implement the Reduced Representation Bisulfite Sequencing method 
for genome-wide DNA methylation analysis with human embryonic stem 
cell samples before proceeding to clinical samples. (I) 
2. To characterise genetic risk for AD in the Finnish study population, 
identify blood DNA methylation markers for AD in twin pairs discordant 
for the disease with RRBS and implement and utilise bisulphite 
pyrosequencing in the validation of the differentially methylated regions 
(DMR). (II) 
3. To identify AD-associated DNA methylation markers in hippocampus 
and compare blood and brain DNA methylomes in AD. (II) 
4. To implement a method for plasma circulating cell-free DNA (cfDNA) 
methylation analysis and identify differences in twin pairs discordant for 
episodic memory performance. (III) 
5. Implement patient-derived induced pluripotent stem cell lines and brain 
organoid models to study disease mechanisms in vitro. 
In addition to these goals, during project III an additional objective was to collect a 
new Finnish twin cohort sample set including blood, plasma and peripheral blood 
mononuclear cell (PBMC) samples for studying epigenetic markers associated with 
EM impairment. 
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4 Materials and Methods 
4.1 Materials 
4.1.1 Cell cultures (I) 
The HS360 and H9 hESC lines were cultured in Turku Centre for Biotechnology on 
feeder cultures with human foreskin fibroblasts that had been mitotically inactivated. 
Before experiments, the cells were cultured at least two passages in feeder-free 
conditions in mTeSR1 medium on Matrigel-coated plates. The H7, H14 and Shef5 
lines had been cultured in Sheffield UK as described previously (Lund et al., 2013). 
In addition, NT2D1 human myeloma, CCRF-CEM human acute lymphocytic 
leukaemia and 2120Ep human embryonal carcinoma cell lines were included in the 
differential methylation analysis in study I. The cell samples were utilised in 
implementing the RRBS protocol and characterising DNA methylation differences 
between normal and karyotypically abnormal hPSCs. H9 and HS360 hESC lines 
were cultured and utilised in cerebral organoid model implementation. 
4.1.2 Twin blood samples (I, II, III) 
4.1.2.1 Finnish twin samples 
The ethylenediaminetetraacetic acid (EDTA) stored blood samples from the Finnish 
twin pairs discordant for AD, who were included in the peripheral blood DNA 
methylation analysis (II), were obtained from the Older Finnish twin cohort (born 
1922-1937), excluding four additional twin pairs born 1915-1950. During the cohort 
study, a total number of 2,483 individuals had been screened via phone interviews 
(Järvenpää et al., 2002). Discordant twin pairs were invited to neurophysiological 
examinations and PET and MRI characterisation and blood sampling between the 
years 2000 and 2008. Alzheimer’s disease diagnosis was made according to the 
overall examination results for 29 pairs. (Kaprio and Koskenvuo, 2002; Järvenpää et 
al., 2003, 2004; Virta et al., 2008; Scheinin et al., 2011; Kaprio, 2013) 
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During study III, additional blood samples from Finnish twins were collected 
(Table 2). A total number of 1,817 individuals from the Older Finnish twin cohort 
were screened via phone interviews between the years 2013 and 2017 (Kaprio and 
Koskenvuo, 2002; Lindgren et al., 2019). Seventeen twin pairs and eight non-twin 
controls participated PET, MRI and neurophysiological testing and blood sampling 
at Turku PET Centre. In addition, two single twins took part in the examination 
since the co-twins could not attend imaging. From the 17 twin pairs, 8 were 
monozygotic and 9 dizygotic. The twins were defined with amnestic mild cognitive 
impairment (aMCI) if the z-scores in the two EM tests were less than or equal to 
minus one. The two tests included the delayed word list recall from the Consortium 
to Establish a Registry for Alzheimer's disease Neuropsychological Battery 
(CERAD-NB) and the Logical Memory delayed recall from the Wechsler Memory 
Scale-Revised (WMS-R) (Jak et al., 2009; Sotaniemi et al., 2012). Seven twin 
pairs, two monozygotic and five dizygotic, who participated in the examinations 
at PET centre before July 2016, were selected for characterisation of the plasma 
cfDNA methylation profiles. 
4.1.2.2 Swedish twin samples 
The peripheral blood DNA samples from Swedish twin pairs discordant for AD 
(born 1907-1953) were obtained from the Swedish Twin Registry (Magnusson et al., 
2013). The samples had been collected before (120 pairs) or after (29 pairs) AD 
diagnosis was made and combined from three Swedish twin studies: the Swedish 
Adoption/Twin Study of Aging (SATSA), the Study of Dementia in Swedish Twins 
(HARMONY) and TwinGene (Gatz et al., 1997, 2005; Finkel et al., 2005; 
Magnusson et al., 2013). 
4.1.3 Human brain tissue samples (II) 
The frozen post-mortem human brain tissue samples analysed in study II were 
obtained from NIH NeuroBioBank. The samples consisted of tissue from 
hippocampus, including dentate gyrus. The samples had been collected from six AD 
cases and six age-matched controls (57-90 years). Both case and control groups 
included two females and four males. One of the AD case samples was excluded 
from the analyses because the sample was in fact from the amygdala, according to 
the neuropathological examination. 
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4.1.4 Human iPSC lines reprogrammed from peripheral 
blood mononuclear cells 
Induced pluripotent stem cells were reprogrammed from PBMCs collected from 
three individuals: a dizygotic twin pair (DZ-1/DZ-2) and a single monozygotic twin 
(MZ-1). Figure 3 shows a microscope image of the iPSCs reprogrammed from DZ-
1 peripheral blood mononuclear cells. The iPSC lines were reprogrammed at Glykos 
Finland Oy with the CytoTune™ -iPS Sendai Reprogramming Kit and stored in 
liquid nitrogen for later use.  
 
Figure 3. Induced pluripotent stem cells reprogrammed from DZ-1 peripheral blood mononuclear 
cells. 
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Table 2. Characterisation of the twin cohort samples collected in project III. 
ID Twin 
pair ID 
Age Gender APOE* CERAD-NB  
z-score 
WMS-R 
z-score 
EM 
status 
Plasma 
cfDNA 
MZ-1 1 74 male 33 -2.5 -1.0 aMCI X 
MZ-2 1 74 male 33 -2.5 -2.8 aMCI X 
MZ-3 2 74 male 33 0.3 -1.0 normal 
 
MZ-4 2 74 male 33 -2.5 -2.3 aMCI 
 
MZ-5 3 75 male 33 0.8 1.6 normal X 
MZ-6 3 75 male 33 -0.3 0.1 normal X 
MZ-7 4 74 female 33 -1.4 -1.3 aMCI 
 
MZ-8 4 74 female 33 0.3 -2.3 normal 
 
MZ-9 5 71 female 34 -0.8 -1.3 normal 
 
MZ-10 5 71 female 34 -1.4 -1.0 aMCI 
 
MZ-11 6 73 male 44 -1.4 -1.0 aMCI 
 
MZ-12 6 73 male 44 -0.8 -0.5 normal 
 
MZ-13 7 71 male 34 -0.3 2.7 normal 
 
MZ-14 7 71 male 34 -2.5 1.6 normal 
 
DZ-1 8 75 female 33 1.4 3.5 normal 
 
DZ-2 8 75 female 33 -1.4 -1.8 aMCI 
 
DZ-3 9 75 female 33 -1.4 -1.0 aMCI X 
DZ-4 9 75 female 33 0.3 0.8 normal X 
DZ-5 10 74 male 33 -0.8 -0.2 normal X 
DZ-6 10 74 male 33 -0.8 -0.2 normal X 
DZ-7 11 74 female 33 -0.3 -0.2 normal 
 
DZ-8 11 74 female 33 -2.5 -0.2 normal 
 
DZ-9 12 74 male 34 0.3 0.3 normal X 
DZ-10 12 74 male 34 -3.1 -3.1 aMCI X 
DZ-11 13 72 female 33 1.4 -0.2 normal X 
DZ-12 13 72 female 34 -2.5 -3.1 aMCI X 
DZ-13 14 72 female 44 -1.9 -2.3 aMCI X 
DZ-14 14 72 female 34 1.4 0.8 normal X 
DZ-15 15 72 female 34 -1.4 -1.3 aMCI 
 
DZ-16 15 72 female 44 -0.3 -1.5 normal 
 
DZ-17 16 75 male 34 -0.8 -1.3 normal 
 
DZ-18 16 75 male 34 0.3 -0.5 normal 
 
HC-1 
 
70 male 33 0.8 2.2 normal 
 
HC-2 
 
73 female 23 0.8 0.3 normal 
 
HC-3 
 
76 female 33 0.8 0.6 normal 
 
HC-4 
 
74 male 33 -0.3 0.6 normal 
 
HC-5 
 
71 female 33 0.8 4.0 normal 
 
HC-6 
 
73 female 23 0.8 3.7 normal 
 
HC-7 
 
72 male 13 1.9 1.9 normal 
 
HC-8 
 
76 male 33 -0.3 0.1 normal 
 
MZ: monozygotic twin, DZ: dizygotic twin, HC: healthy control, *APOE genotype 
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4.2 Methods 
4.2.1 Human tissue sample processing 
4.2.1.1 DNA isolation from EDTA blood samples (I, II) 
DNA was isolated from EDTA blood samples with Qiagen QIAamp Blood Mini and 
Maxi kits according to the manufacturer’s protocol. Isolated DNA concentrations we 
measured with Thermo Scientific NanoDrop 2000 and genomic DNA quality 
checked with gel electrophoresis. 
4.2.1.2 Isolation of plasma and peripheral blood mononuclear cells from 
blood samples (III) 
Blood samples were collected at Turku PET Centre into BD Vacutainer® CPT™ 
tubes and processed at Turku BioScience Centre within one hour of sampling. To 
separate plasma and PBMCs, the tubes were first centrifuged 20 minutes at 1,500 
RCF (relative centrifugal force) in room temperature. Plasma was transferred into 
one-millilitre aliquots in low-binding Eppendorf tubes, centrifuged again 10 min at 
1,300 RCF in +4°C to remove residual cells, transferred into clean Eppendorf tubes, 
snap-frozen on dry ice and stored in -80°C. The number of PBMCs was counted in 
a cell counting chamber, PBMCs were transferred into 0.5 ml aliquots in cryotubes, 
including 10 % DMSO (dimethyl sulfoxide), and frozen in cell freezing container in 
-80°C. After two days the PBMC cryotubes were transferred into -150°C for long 
term storage. 
4.2.1.3 DNA isolation from plasma (III) 
Circulating cfDNA was isolated from plasma samples with Qiagen QIAamp 
Circulating Nucleic Acid Kit using Qiagen QIAvac 24 Plus vacuum system 
according to the manufacturer’s protocol. Isolated DNA amounts were measured 
with Invitrogen Qubit 2.0 fluorometer dsDNA HS assay and quality checked with 
Agilent Technologies Bioanalyzer 2100 DNA High Sensitivity assay. 
4.2.1.4 DNA isolation from frozen brain tissue samples (II) 
The fresh-frozen brain tissue samples were cut on microscope slides in the 
microtome. The frozen tissue slides were stained with anti-hyaluronan tags and taken 
into neuropathological examination by a pathologist, to ensure that the tissue 
samples were from the correct brain region. DNA was isolated from frozen brain 
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tissue slides with Qiagen QIAamp DNA Micro Kit according to the manufacturer’s 
protocol with few modifications. Lysis buffer (ATL) was pipetted on the tissue slide, 
tissue was detached from the glass slide with a cell scraper and the mix containing 
the tissue sample and lysis buffer was transferred into 1.5 ml Eppendorf tube for the 
following steps. 
4.2.2 Targeted sequencing of single nucleotide 
polymorphisms associated with Alzheimer’s disease 
(II) 
The 21 SNPs (single nucleotide polymorphism) previously associated with AD and 
APOE genotypes were characterised with Illumina TruSeq Custom Amplicon 
sequencing assay from the Finnish twin samples, included in the blood DNA 
methylation RRBS analysis. The sequencing panel was designed in Illumina 
DesignStudio software. The samples were sequenced with Illumina MiSeq 
sequencing platform and 500-cycle chemistry. Variants were called in Illumina 
BaseSpace cloud computing service. Genetic risk scores (GRS) were calculated and 
GRS association with AD was tested with a generalised linear model in R software 
version 3.4.3 using packages lmtest, multiwayvcov and fmsb (R Core Development 
Team, 2013; Zeileis and Hothorn, 2015; Nakazawa, 2016; Graham, Arai and 
Hagströmer, 2018).  
4.2.3 DNA methylation analysis 
4.2.3.1 Reduced Representation Bisulfite Sequencing (I, II) 
RRBS was utilised in the characterisation of genome-wide DNA methylation 
profiles from different cell lines (I), human peripheral blood samples (II) and human 
post-mortem brain tissue samples (II). The sequencing libraries were prepared as 
described previously (Boyle et al., 2012). However, the samples were pooled 
together only after confirming the quality of each final library instead of pooling 
directly after the ligation of indexed sequencing adapters. Library qualities were 
checked with Agilent Technologies Bioanalyzer 2100 High Sensitivity DNA Assay 
and concentrations measured with Invitrogen Qubit 2.0 Fluorometer dsDNA HS 
Assay. The RRBS libraries were sequenced with 1x50 bp chemistry in Illumina 
HiSeq 2000/2500/3000 machines. Sequencing reads were trimmed with Trim Galore 
software and mapped to hg19 (cells, blood) or hg38 (brain) reference genomes using 
Bismark (Krueger and Andrews, 2011; Krueger, 2012). Differential methylation 
between samples was analysed using methylKit (cells and brain) or RADMeth 
(blood) software (Akalin et al., 2012; Dolzhenko and Smith, 2014). While analysing 
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the blood DNA methylation data, BACON software was utilised in calculating and 
correcting for bias caused by unobserved factors, like cell type heterogeneity (van 
Iterson, van Zwet and Heijmans, 2017). 
4.2.3.2 Targeted bisulphite pyrosequencing (II) 
Targeted bisulphite pyrosequencing was used to validate one of the DMRs that were 
detected with RRBS in peripheral blood of AD-discordant twin pairs. The genomic 
region chr10:1405336-1405409 (hg19) was analysed with pyrosequencing. PCR 
primers (5′-gtaatttagtggtgttgttgaat-3′ and 5′-biotin-cctaacccccaaccaacttcttactac-3′) 
and sequencing primer (5′-gggttgagttaagtgtgtttggtaga-3′) were designed in Qiagen 
PyroMark AssayDesign SW 2.0. DNA samples were bisulphite converted with 
Qiagen Epitect Fast DNA Bisulfite Kit and amplified with Qiagen PyroMark PCR 
kit. Amplicons were sequenced with Qiagen PyroMark Q24 Advanced platform and 
methylation values called with Qiagen PyroMark Q24 Advanced 3.0.0 software. 
Statistical analysis of differential methylation association with AD was carried out 
in R version 3.4.3 and packages lme4 v1.1-15, car v2.1-6, survival 2.42-4, coxme 
2.2-10 (Fox and Weisberg, 2011; R Core Development Team, 2013; Bates et al., 
2015; Therneau, 2015, 2018). 
4.2.3.3 Plasma cell-free DNA bisulphite sequencing (III) 
Plasma circulating cfDNA methylation profiles were analysed with a custom 
protocol that was implemented during the project III. The sequencing libraries were 
prepared from seven twin pairs, including two monozygotic twin pairs concordant 
for aMCI, one dizygotic twin pair concordant for aMCI and four dizygotic twin pairs 
discordant for aMCI. The isolated DNA samples were first end-repaired and A-tailed 
with Klenow fragment. Unmethylated lambda DNA was added to the samples to 
control for bisulphite conversion efficiency. Illumina TruSeq sequencing adapters 
were ligated to the a-tailed DNA fragments and library samples purified with 
AMPure XP Beads. Libraries were bisulphite converted with Invitrogen MethylCode 
Bisulfite Conversion Kit and amplified in an 18 cycle PCR. Finally, the libraries 
were purified twice with AMPure XP beads, with 1.2 and 1.5 bead concentrations, 
and final library quality was characterised with Agilent Technologies Bioanalyzer 
2100 DNA High Sensitivity Assay and concentrations measured with Qubit 2.0 ds 
DNA HS assay. The libraries were sequenced in Illumina HiSeq 2500 and 3000, 
sequencing reads trimmed with Trim Galore version 0.4.1 and trimmed reads 
mapped into reference genome (hg38) with Bismark 0.14.5 (Krueger and Andrews, 
2011; Krueger, 2012). Different R software packages were tested for differential 
methylation analysis, including RnBeads version 1.6.1, dmrseq version 1.0.12 and 
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methylKit version 1.7.9, however, the final analyses were carried out with PQLseq 
version 1.1 (Akalin et al., 2012; Korthauer et al., 2019; Müller et al., 2019; Sun et 
al., 2019). Methylation differences associated with the episodic memory z-score 
were tested within the whole seven-twin pair sample set using a generalised linear 
mixed-effects model. 
4.2.4 APOE genotyping (II) 
Two methods were utilised in the characterisation of the APOE genotypes (rs7412 
and rs429358) from the human DNA samples. 404 DNA samples collected from 
Finnish and Swedish twins were sent to LGC Genomics to be genotyped with a 
custom qPCR based KASP assay. However, KASP genotyping failed from a few 
samples, thus APOE genotypes from four individuals were characterised with 
pyrosequencing. Pyrosequencing primers had been designed in PyroMark 
AssayDesign 2.0 software. The PCR primers for rs7412 were 5’-
CTCCGCGATGCCGATGAC-3’ and 5’-biotin-CCCCGGCCTGGTACACTG-3’ 
and sequencing primer 5’-CGATGACCTGCAGAA-3’. For rs429358 the PCR 
primers were 5’-biotin-CGCGGACATGGAGGACGT-3’ and 5’-
CCTCGCCGCGGTACTGCA-3’ and the sequencing primer 5’-
ACTGCACCAGGCGGC-3’. The DNA samples were amplified with Qiagen 
PyroMark PCR kit according to the manufacturer’s protocol and sequenced in 
Qiagen PyroMark Q24 Advanced. Variants were called with Qiagen PyroMark 
Advanced 3.0.0 software. 
4.2.5 Single-cell RNA sequencing (II) 
10X Genomics Chromium single-cell RNA sequencing platform was utilised in 
analysing the single-cell RNA expression profiles of PBMCs from two Finnish 
monozygotic twin pairs discordant for cognitive function. Chromium™ controller 
and Single Cell 3’ Reagents kit (10x Genomics) were used in the preparation of the 
single-cell RNA sequencing libraries. Libraries were sequenced with Illumina 
HiSeq2500 and the sequencing data pre-processed with Cell Ranger software (v. 
1.2.0, 10x Genomics) and mapped into hg38 reference genome. Single-cell gene 
expression profiles for each sample were normalised and analysed with Seurat R 
package v. 1.4.0.9 (Butler et al., 2018). 
Mikko Konki 
 44
4.2.6 Human pluripotent stem cell culturing and cerebral 
organoid differentiation 
H9 and HS360 hESC lines were cultured in feeder-free conditions on Matrigel 
(Corning) coated plates with mTeSR1 culturing medium (STEMCELL 
Technologies). Culturing medium was changed daily and the cells were passaged 
using dispase. The hESCs were differentiated into cerebral organoids according to 
the protocol designed by Lancaster and her group (2014). Briefly, PSCs are 
differentiated into embryoid bodies (EB) on a 96-well plate. The EBs are cultured 
on 96-well plate until germ layers start to differentiate. Next, the EBs are transferred 
into larger wells, where neuroepithelial differentiation is inducted. The primitive 
neuroepithelial tissues are transferred into Matrigel droplets, expanded, and after 
further differentiation, they are moved into stationary cultures in 125 ml spinning 
bioreactors.  
4.2.7 Cerebral organoid staining and imaging 
Cerebral organoids were collected from the bioreactor, washed with PBS and fixed 
with paraformaldehyde. After fixing, the organoids were cryoprotected by 
incubating in 30 % sucrose and PBS in +4º C overnight. After cryoprotection, the 
fixed organoids were mounted into freezing blocks in mounting medium for 
cryotomy. Blocks were frozen in isopentane on dry ice and stored in -80º C. The 
blocks containing the organoids were cut into 40 µm thick slides in a cryostat and 
stained with anti-DAPI, -SOX2, -TUJ1 and -DCX antibodies. The organoids were 
imaged using a Zeiss LSM 780 confocal microscope. 
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5 Results 
5.1 Implementation of RRBS for genome-wide 
DNA methylation analysis of human stem cell 
and blood samples (I) 
Before working with the clinical blood DNA samples isolated from the twin pairs 
discordant for AD, the RRBS protocol was tested and implemented with DNA from 
human cell lines and peripheral whole blood. The cell lines included hESC and 
cancer cell lines. Figure 4 shows the Bioanalyzer electropherograms of RRBS 
libraries prepared from human stem cell and peripheral blood DNA. The overall size 
distribution is very similar between all samples even though the concentrations 
differ. Sequencing of the RRBS libraries prepared from human cell samples 
produced 9.8 to 24.4 million raw reads per sample. After quality processing and 
trimming, between 5.5 to 14.04 million reads per sample were uniquely mapped into 
the reference genome (hg19) with 56.6%-73.9% mapping efficiency. Between 945K 
and 1.5 million CpG sites were detected with 5x sequencing coverage in each 
sample. 
5.2 Catalase gene is silenced via epigenetic 
mechanisms in karyotypically abnormal hESC 
lines 
With the DNA methylation data from the cell samples, we compared differences 
between karyotypically normal and abnormal human hESC lines as well as hESC 
lines before the transformation, however, with a tendency to accumulate karyotypic 
abnormalities. By comparing DNA methylation and gene transcription profiles, we 
discovered that a key antioxidant enzyme catalase is silenced in abnormal hESCs via 
DNA methylation and the changes can be detected already before karyotypic 
abnormalities become evident. Methylation of the CpG site in catalase (CAT) gene 
promoter was increased in abnormal cells by 68 % (p=2.33*10-5) in comparison to 
normal cell lines. CAT expression was also decreased in abnormal cells according to 
the transcriptome data (fold change: -8.47, p=9.08*10-23). 
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Figure 4. Bioanalyzer electropherograms of RRBS libraries prepared from human stem cell and 
blood DNA. 
5.3 Genetic risk for Alzheimer’s disease in Finnish 
disease-discordant twin pairs (II) 
Since genetics have such a significant impact on AD risk, we characterised genetic 
AD risk in the Finnish twin study participants before analysing their blood DNA 
methylation profiles. The 21 SNP positions that had previously been associated with 
altered AD risk were characterised from 9 MZ and 12 DZ twin pairs discordant for 
AD, 9 un-related controls and 18 un-related AD cases (Figure 5). Monozygotic 
twins had identical genotypes in comparison to the co-twins, as expected. Dizygotic 
twin pairs had differences in 2-10 variant positions compared to the co-twins. 
Genetic risk scores were calculated for the different study groups; however, the 
scores were not associated with AD status according to generalised linear regression 
model (Wald test z value < 1, Pr(>[z]) > 0.5). (II: table 2) 
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Figure 5. Genetic Alzheimer’s disease risk profiles of the Finnish study participants. SNPs 
associated with increased AD risk are marked red and protective SNPs are blue. Dark 
colours indicate biallelic risk or protective variant and light colours indicate monoallelic 
variant. 
5.4 Peripheral blood DNA methylation differences 
in twin pairs discordant for Alzheimer’s disease 
(II) 
To identify possible DNA methylation markers for AD in peripheral blood, we 
characterised genome-wide DNA methylation profiles from blood samples and 
compared differences within 11 MZ and 12 DZ twin pairs discordant for AD. The 
differences between MZ and DZ twins were analysed separately at first. Only CpG 
sites detected in at least four twin pairs, both twins of the pair, per study group with 
10x or higher sequencing coverage were included in the differential methylation 
analyses. With this threshold, we detected 838,967 sites in MZ twin and 817,103 in 
DZ twin groups. The differential methylation cut-off criteria were median 
methylation difference of at least 15 % between discordant twins and Benjamin 
Hochberg false discovery rate adjusted p ≤ 0.05 Within MZ twins, we detected 912 
differentially methylated sites, 434 of which were more and 478 were less 
methylated in AD cases versus controls. A total number of 2112 CpG sites were 
differentially methylated between AD discordant DZ twins. 1344 of these sites were 
more and 768 were less methylated in cases when compared to controls. Comparison 
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of the two datasets from MZ and DZ twins revealed 11 CpG sites that were 
differentially methylated in both groups. Seven CpG sites were more and four were 
less methylated in AD cases than in controls. The closest or overlapping genes to 
these 11 CpG sites were defensin alpha 1 (DEFA1), t-SNARE domain containing 1 
(TSNARE1), DEAF1 transcription factor (DEAF1), ArfGAP with RhoGAP domain, 
ankyrin repeat and PH domain 2 (ARAP2), canopy FGF signalling regulator 1 
(CNPY1), adenosine deaminase RNA specific B2 (ADARB2), Rho GTPase 
activating protein 8 (ARHGAP8), general transcription factor IIIC subunit 2 
(GTF3C2), actin alpha 1, skeletal muscle (ACTA1), semaphorin 5A (SEMA5A) and 
CAP-Gly domain-containing linker protein 2 (CLIP2). (Table 3, II: Figure 1) 
Table 3. Differentially methylated CpG sites in peripheral blood of Finnish twin pairs discordant 
for Alzheimer’s disease. 
CpG site annotation MZ twins DZ twins All twins 
Location (hg19) Closest gene Meth. 
Diff. % 
p-value Meth. 
Diff. % 
p-
value 
Meth. 
Diff. % 
p-value 
chr8:143407666 TSNARE1 24.92 8.89E-03 20.40 0.00 22.66 2.57E-04 
chr7:155327302 CNPY1 18.18 2.55E-02 17.46 0.01 17.82 3.19E-03 
chr22:45193257 ARHGAP8 17.11 5.98E-04 18.40 0.01 17.75 8.64E-05 
chr10:1405392 ADARB2 17.03 3.05E-03 23.67 0.05 20.35 1.43E-03 
chr4:33809696 ARAP2 16.18 1.29E-04 16.60 0.01 16.39 1.17E-05 
chr11:646372 DEAF1 15.99 4.05E-03 15.82 0.00 15.91 2.35E-06 
chr8:6875660 DEFA1/-1B/-3 15.49 2.55E-02 21.25 0.02 18.37 3.90E-03 
chr7:73825342 CLIP2 -15.95 1.98E-02 -20.54 0.04 -18.25 6.13E-03 
chr1:229540297 ACTA1 -18.18 9.10E-04 -19.02 0.02 -18.60 1.71E-04 
chr2:27580515 GTF3C2 -22.45 6.61E-04 -29.82 0.02 -26.14 1.27E-04 
chr5:8851435 SEMA5A -27.75 6.55E-03 -31.67 0.01 -29.71 8.55E-04 
 
5.5 Alzheimer’s disease-associated DNA 
methylation marks in the brain and correlation 
with blood DNA methylation markers (II) 
Next, the goal was to find out whether the blood DNA methylation marks associated 
with AD can also be detected in brain tissue. Genome-wide DNA methylation 
profiles were analysed in the hippocampus, including dentate gyrus tissue samples 
from four AD cases and six un-related controls. Differential methylation cut-off was 
defined as mean methylation difference of at least 15 % between cases and control, 
consistent methylation difference between all cases and controls and multiple test 
corrected p<0.05. With these criteria, we detected 114 CpG sites that were less 
methylated and 87 that were more methylated in AD cases in comparison to controls. 
These 201 sites located within or close to 176 different genes. Comparison of the 
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gene lists from differentially methylated sites in peripheral blood of Finnish twin 
pairs discordant for AD and brain tissue from un-related AD cases and controls 
revealed one common gene ADARB2. In both brain and blood, the differentially 
methylated sites were located within the same region chr10:1404752-1405717 in 
exon 3 of the ADARB2 gene. (II: Figure 2) 
5.6 Expression of the differentially methylated 
genes in peripheral blood (II) 
The next research question was whether the genes located closest to DMRs in the 
blood are also differentially expressed in blood cells in AD. At first, we examined 
the expression of the eleven differentially methylated genes (Table 3) in a published 
peripheral blood expression data from 121 AD cases and 122 controls (Sood et al., 
2015). Nine of the eleven genes were expressed in the blood; however, there were 
no differences in expression of these genes between AD cases and controls. 
Expression of these genes was also characterised with single-cell RNA sequencing 
in PBMC samples from two Finnish twin pairs discordant for EM performance. The 
single-cell RNA sequencing analysis revealed no major differences in the 
proportions of PBMC populations or expression of the differentially methylated 
genes in PBMCs between EM impaired and control twins. Expression of six of the 
eleven differentially methylated genes, including ARAP2, CLIP2, DEAF1, GTF3C2, 
TSNARE1 and ADARB2, was detected in the PBMC samples. 
5.7 Targeted validation of Alzheimer’s disease-
associated differential methylation in ADARB2 
gene (II) 
Since the genomic region chr10:1,405,405-1,405,366 (hg19) in exon three of 
ADARB2 gene was differentially methylated both in the blood of Finnish twin pairs 
discordant for AD and brain tissue samples from AD cases versus controls, this 
region was selected for validation assay. The next question was whether the 
peripheral blood methylation difference in the region can be validated in an extended 
twin cohort, including Swedish twins, and is the methylation status predictive for 
AD. DNA methylation in the region chr10:1,405,405-1,405,366 (hg19) was analysed 
with targeted bisulphite pyrosequencing in peripheral blood samples of 62 twin pairs 
discordant for AD. This included 33 Finnish and 29 Swedish twin pairs. Statistical 
testing was carried out with a linear mixed-effects model (lme) (Bates et al., 2015). 
The methylation status of the region was confirmed to be associated with AD (Wald 
test t value 4.68, II: Fig. 3). In the final statistical model, also gender, zygosity and age 
influenced the methylation status. DNA methylation difference was greater between 
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dizygotic than monozygotic twin pairs (estimate 7.67%, standard error (SE) 1.44, Wald 
t value 5.34). Analysing males and females separately revealed that methylation was 
increased in male cases (Wald t value 6.10), however, in females the methylation was 
increased only in cases who had APOE ε34/44 genotype (Wald t value 3.44) but not in 
cases who had APOE ε33 genotype (Wald t value -1.67). Additional analysis of 60 twin 
pairs from whom smoking data were available revealed that smoking also interacts with 
the disease (estimate 8.10%, SE 1.43, and Wald t value 5.68), however, the disease-
methylation status association is not attenuated even if smoking is included in the 
statistical model (estimate 64.51%, SE 9.23, and Wald t value 6.99). DNA methylation 
in the region was also characterised in blood samples collected from 120 Swedish 
discordant twin pairs 0.5-18.5 years before AD diagnosis. However, the results show 
that methylation the status of the region before AD diagnosis does not predict disease 
outcome (hazard ratio = 1.00, 95% confidence interval = 1.00–1.00, p = 0.63). 
5.8 Plasma cell-free DNA methylation markers for 
episodic memory impairment (III) 
Episodic memory impairment usually causes the first clinical symptoms in dementia 
due to AD. However, AD can currently be clinically diagnosed only at later stages 
when neurodegeneration is more progressed. To identify early markers for AD, we 
implemented a genome-wide bisulphite sequencing method for plasma cfDNA 
methylation analysis and compared differences between Finnish twin pairs 
discordant for EM impairment. The WGBS protocol was successfully implemented 
for the methylation analysis of plasma circulating cfDNA. We characterised 
methylation profiles of 14 twins, including two monozygotic and five dizygotic twin 
pairs, from three nanograms of plasma DNA per individual. The number of CpG 
sites detected with 10x sequencing coverage per sample varied between 4,023 and 
13,414. A vast majority of the detected CpG sites are located in certain hotspots, 
especially centromere and telomere regions of most chromosomes, instead of 
distributing evenly on the genome (III: Fig. 1). 
CpG sites located in low complexity DNA regions, like repeating elements, from 
the data. Differential methylation associated with episodic memory z-score was 
tested with PQLseq R package that implements a binomial mixed-effects model. 
Episodic memory z-score was set as the test variable in the analysis. Gender, age, 
zygosity and APOE genotype included as fixed effects and twin pair ID as a random 
effect in the model. Differential methylation was analysed over 2.089 CpG sites that 
were detected in all fourteen twin samples with 10x sequencing coverage. 99.52 % 
of these sites located in intergenic regions of the genome. We detected no statistically 
significant differentially methylated CpG sites (multiple test corrected p<0.05) 
associated with EM performance in the twins. 
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5.9 Human pluripotent stem cell models for 
Alzheimer’s disease 
Peripheral blood mononuclear samples were collected from seven monozygotic and 
nine dizygotic twin pairs and eight non-twin individuals, a total number of 40 
individuals. Induced pluripotent stem cells were successfully reprogrammed from 
three individuals, a dizygotic twin pair (DZ-1/DZ-2) and a single monozygotic twin 
(MZ-1), at Glykos Finland Oy (Table 2). The iPSC cell lines expressed high levels 
of PSC markers TRA-1-60, SSEA-4 and H type 1 (Figure 6). Cerebral organoids 
were successfully differentiated from hESCs and maintained in the bioreactors for 
three months. Staining the organoids revealed a structured organisation of neurons 
and neuronal progenitor cells in the developing organoid tissue (Figure 7). 
 
Figure 6. Induced pluripotent stem cell line reprogrammed from MZ-1 peripheral blood 
mononuclear cells. The iPSCs population was identified and selected according to side 
scatter (SSC) and forward scatter (FSC) values via flow cytometry (a.). The iPSCs 
expressed high levels of pluripotent stem cell markers TRA-1-60 (b.), SSEA-4 (c.) and 
H type 1 (d.) and formed typical colonies in in vitro culture (e.). 
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Figure 7. Cerebral organoid staining for DNA (DAPI: blue), neurons (TUJ1: green), neuronal 
progenitors (DCX: red/SOX2: purple) 
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6 Discussion 
6.1 RRBS in genome-wide DNA methylation 
analysis 
RRBS method was successfully implemented for genome-wide DNA methylation 
analysis of hESC, blood and post-mortem brain tissue DNA samples, during this 
project. In the peripheral blood DNA samples, we detected 838,967 sites in MZ twins 
and 817,103CpG in DZ twins with required 10x sequencing coverage in at least four 
twin pairs per twin group. This number is very close to the number of sites detected 
with the highest coverage microarrays, which is currently 850,000 sites, showing 
that the genomic coverage we reached with RRBS is similar to microarrays. The 
preparation of first of the blood DNA RRBS libraries was started already before the 
current highest coverage Illumina Infinium MethylationEpic microarray method was 
released. While the analysis of the methylation data would most likely have been a 
lot easier and more straightforward with microarrays, we would have detected only 
about half the number of CpG sites with the Illumina 450K array that was available 
at the time. 
In comparison to WGBS, the genomic coverage we reached in the different 
sample sets is quite low, as expected. However, WGBS libraries are still quite 
expensive to sequence as reaching an adequate sequencing depth requires deeper 
sequencing. Deeper sequencing produces more sequencing data, which requires 
more storage and computing capacity to process the data. WGBS data also contains 
vast amounts of sequence reads that do not contain any methylation sites and are 
discarded in methylation calling step in data analysis. Overall, RRBS is a well-suited 
method for what it has been designed for: it quantifies DNA methylation at CpG rich 
genomic regions, which are, at least according to current knowledge, the most 
interesting in terms of functional relevance. Another possible option for this project 
would have been to analyse the samples with array-based methods. The per sample 
analysis costs for RRBS is in the same range as the newest version of microarrays, 
whereas WGBS is a lot more expensive. RRBS also provides a possibility to scale 
the costs of the experiments, since the most expensive step in the protocol is 
sequencing. Deeper sequencing will be more expensive but also will detect more 
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sites, whereas shallow sequencing is not so expensive but may also give interesting 
results at least if the number of samples per study group is adequate. 
Even though the coverage in terms of the number of the methylation sites 
detected is similar between RRBS and microarrays, the actual coverage, where the 
detected sites are located in the genome, can still be quite different. Methylation 
arrays are for the most part targeted towards regions where methylation most likely 
has a functional impact, like gene promoters. In RRBS analysis these same regions 
that usually have high CpG density are also enriched, however, the selection of the 
target regions is also randomised as no regions are specifically targeted. (Stirzaker 
et al., 2014) This allows RRBS to detect new methylation markers, not included in 
the methylation arrays, but may also cause unreliability issues in the analysis since 
specific CpG sites are detected only in a subset of the samples instead of all of them. 
Thus, in our peripheral blood DNA methylation analysis, the CpG sites had to be 
detected in at least four discordant twin pairs in a twin group to be included in the 
analysis. 
To conclude, RRBS was a well-suited method for discovery of methylation 
markers candidates for AD. While methylation arrays could also have been a good 
option, none of the DMRs we detected with RRBS is included in the arrays that are 
currently available. The array-based analysis could also reveal as interesting 
differences as we detected with RRBS, however, the results would most likely be 
different. 
6.2 Peripheral blood DNA methylation markers for 
Alzheimer’s disease 
We discovered DNA methylation differences in 11 genomic regions in peripheral 
blood of twin pairs discordant for AD, indicating that epigenetic markers associated 
with the disease can be detected in peripheral tissues. Whether the methylation levels 
in these sites affect gene expression or not, requires further inspection. However, our 
results show no differences in expression of the genes closest to the DMRs in 
PBMCs of twins who have EM impairment in comparison to controls. Expression of 
9 out of the 11 differentially methylated genes was detected in peripheral blood in a 
study by Sood and her group (2015), yet they discovered no differences between AD 
patients and controls. Overall, the preliminary results indicate that AD-associated 
differential methylation in these regions does not affect gene expression in peripheral 
blood. 
One of the 11 DMRs in blood was also differentially methylated in hippocampus 
tissue samples from AD patients in comparison to controls. Alzheimer’s disease-
associated differential methylation in this region, located in the third exon of the 
ADARB2 gene, was also validated in a larger cohort including Swedish twin pairs 
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discordant for the disease. Even though the result was confirmed in the extended 
cohort, there is a lot of variation in the methylation status of this region between 
individuals. Our results also showed that the methylation status does not predict AD 
before the disease can be diagnosed. Thus, utilising peripheral blood methylation 
markers in AD diagnosis would most likely require a combinatory analysis of several 
distinct regions. 
The reason why DNA methylation markers associated with AD can be detected 
in peripheral blood remains unclear. It may be that external factors, like environment, 
lifestyle, other diseases etc. give rise to these epigenetic changes in not only neuronal 
tissues but also other peripheral tissues like blood; however, the responses to these 
changes vary from tissues to tissues. In other words, the problems arise only in those 
tissues, where the affected genes are functionally important. A study by Braun and 
her group (2019) concluded that blood DNA methylation is indeed well correlated 
with DNA methylation in living brain tissue. How the genes that are differentially 
methylated in blood in AD contribute to the disease pathogenesis, requires still more 
research, even though many of the differentially methylated genes have known roles 
in neuronal tissue development and functions. 
6.3 ADARB2 – a biomarker candidate for 
Alzheimer’s disease 
Our most promising finding was the AD-associated differential methylation in the 
third exon of the ADARB2 gene in the blood of twin pairs discordant for the disease. 
However, it still requires more research to evaluate this marker’s potential as a 
diagnostic indicator for AD. By definition, AD biomarkers have to have certain 
important characteristics: a biomarker has to have a proven function in the 
pathogenesis of the disease and the test has to be sensitive enough to detect AD at 
the expected rate and specific to distinguish AD from other dementias. Besides, a 
biomarker test should be relatively simple to perform, non-invasive for the patients, 
reliable, reproducible and not too expensive. (Davies et al., 1998) 
There is growing evidence that ADARB2 may have important functions in 
regulating memory and learning and even cognitive impairment in AD. ADARB2 is 
a member of RNA editing enzymes. ADARB2 is expressed specifically in the brain 
where it may regulate RNA editing. In contrast to the other two members of the 
ADAR enzyme family ADARB2, also known as ADAR3, does not have the same 
catalytic domain, thus its functions remain unknown even though there is evidence 
of ADARB2 RNA editing activity in human tissues. (Chen et al., 2000; Savva, 
Rieder and Reenan, 2012; Oakes et al., 2017) Interestingly, a study by Khermesh 
and his group (2016) found out that adenosine to inosine RNA editing, which is 
mediated by ADAR enzymes, is distorted in the hippocampus in AD. A mouse model 
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has also shown that ADARB2 is involved in the regulation of memory and learning 
in mice. (Mladenova et al., 2018) A variant of the ADARB2 gene has also been 
associated with an elevated rate of MCI conversion to AD (Lee et al., 2017). 
Even though previous studies indicate that ADARB2 may be functionally 
important in AD pathogenesis, the actual mechanisms have not been studied, and 
even the gene product’s function in normal conditions is not completely understood. 
Due to inter-individual variability in the methylation level of this region, it is clear 
that this marker alone is not enough to detect AD with sufficient sensitivity. 
However, possible mechanistic studies could in the future give new information on 
whether and how ADARB2 affects AD pathogenesis in neuronal tissue. It remains to 
be studied whether DNA methylation analysis of the ADARB2 region in combination 
with other promising regions could be utilised in AD diagnostics. 
6.4 The differentially methylated genes in the blood 
are associated with neuronal functions and 
disorders 
In addition to the DMR in ADARB2, several of the other DMRs are close to genes 
that are highly expressed in the brain and are involved in neuronal functions. This 
supports our findings and the hypothesis that peripheral blood DNA methylation 
markers can indicate perturbations in the nervous system and neurodegenerative 
diseases, like AD. The DMR in DEAF1 gene had the lowest multiple corrected test 
corrected significance value in the whole blood RRBS analysis. DEAF1 encodes a 
zinc finger transcription factor that is important in embryonal development and is 
highly expressed in brain tissue (Fagerberg et al., 2014). Different variants of 
DEAF1 have been associated with several neuronal and neurodevelopmental 
disorders, like DEAF1 associated neurodevelopmental disorder, autism, epilepsy, 
basal ganglia dysfunction and intellectual disability (Rajab et al., 2015; Gund et al., 
2016; Chen et al., 2017). 
TSNARE1, on the other hand, is expressed in several tissues around the body, 
and specific variants of the gene have been associated with schizophrenia and bipolar 
disorder (Sleiman et al., 2013; Gu et al., 2015). Increased levels of alpha-defensins, 
encoded by DEFA1 gene, have been detected in CSF of AD patients (Szekeres et al., 
2016). SEMA5A gene, which encodes the semaphorin 5A cell membrane protein, is 
expressed widely in different tissues; however, it is very important for neuronal 
development (Goldberg et al., 2004; Fagerberg et al., 2014). Specific variants of the 
genes have been linked to increased Parkinson’s disease risk and SEMA5A 
expression is decreased in autism (Melin et al., 2006; Yu, Wang and Zhang, 2014). 
Semaphorin family of proteins has an important function in the nervous system and 
gene variants and defects in the functional networks of these proteins have been 
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associated with different neurodegenerative diseases, like AD, Parkinson’s disease 
and amyotrophic lateral sclerosis (Quintremil et al., 2019). 
The genome is stored together as a three-dimensional structure where genomic 
regions that are located far away from each other may interact with each other. Thus, 
some of the DMRs we have detected in the blood may also regulate other more 
distant genomic regions and genes, instead of the closest genes that we have mainly 
focused on. The importance of long-range genomic interactions in the three-
dimensional genome has become more and more apparent during recent years due 
to development in genome research methods (Schmitt, Hu and Ren, 2016; 
Schoenfelder and Fraser, 2019; Zheng and Xie, 2019). More research is still required 
to characterise and understand the interactions between distal genomic regions and 
possible disturbances in these mechanisms in diseases like AD. 
Since several of the DMRs are near genes that are expressed in the brain and 
have been linked to neuronal functions and diseases, they may be also functionally 
relevant in AD pathogenesis. This also supports our hypothesis that DNA 
methylation markers for AD can be detected in the blood. Due to limited time and 
resources, we only managed to validate AD-associated DNA methylation difference 
in the ADARB2 gene in the extended cohort, including the Swedish twins. The other 
DMRs, discovered with RRBS, should also be validated to confirm the differential 
methylation and to evaluate their sensitivity in AD diagnosis.  
While targeted bisulphite pyrosequencing was a reliable, reproducible and cost-
efficient method for targeted validation of the ADARB2 regions, the method has its 
weak points as well. The platform that we used, Qiagen PyroMark Q24 Advanced, 
can only analyse up to 24 samples in a sequencing run, which is not very high-
throughput. A higher throughput Q96 version of the machine also exists; however, 
Q24 was the only one available for us. The most difficult and time-consuming part 
of the pyrosequencing protocol is designing and setting-up the sequencing assays for 
each target region. Depending on the genomic sequence, some regions can be even 
impossible to analyse with bisulphite pyrosequencing. For example, the DMR close 
to TSNARE1 gene (chr8:143407666, hg19) consists of highly repetitive DNA 
sequence, making it very difficult to design a working assay for PCR and sequencing 
of the bisulphite converted DNA. However, there are not many competing methods 
available for targeted DNA methylation analysis that the user can target and design 
the assay for, in principle, any target region in the genome. After all, a working 
pyrosequencing assay can produce accurate and quantitative methylation data at 
single-nucleotide resolution.  
More research is also required to understand better, how DNA methylation 
differences in blood correlate to DNA methylation in the brain in AD, whether the 
expression of these genes is regulated via DNA methylation and what are the exact 
functional mechanisms that link these genes to the disease pathogenesis. Studying 
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the functional mechanisms of AD pathogenesis is difficult because even despite the 
extensive amount of research on the field, the disease-causing mechanisms remain 
unclear. 
6.5 DNA methylation markers associated with 
Alzheimer’s disease in the hippocampus 
In the hippocampus samples, we detected 201 differentially methylated CpG sites in 
AD patients versus the controls: 114 of the sites were hypomethylated and 87 
hypermethylated in AD. The main goal of this comparison was to find out whether 
DMRs in blood in AD overlap with DNA methylation differences in a brain region 
that is important for memory and learning. Comparison of the AD-associated DNA 
methylation markers in blood and brain revealed only one common region, which 
located in 3rd exon of the ADARB2 gene. Since the gene is differentially methylated 
in both blood and brain in AD, ADARB2 could have an important role in the disease 
pathogenesis. 
However, the number of hippocampus samples we could acquire and analyse 
was very limited. In the final differential methylation comparison, we included only 
four AD patients and six controls. These samples were acquired from NIH 
Neurobiobank and, while they were matched against age and gender, we do not have 
information on the individuals’ ethnic backgrounds or genetic AD risk profiles and 
could not adjust the analysis for these variables. Thus, there can be relatively high 
genetic and epigenetic variance between the individuals that we do not know of. Due 
to the limited information on the individuals’ backgrounds and the small number of 
samples, we cannot make profound conclusions about the mechanisms of DNA 
methylation perturbations in the hippocampus in AD according to the analysis. 
However, the results are reliable enough to support the findings from the blood 
methylation analysis. 
We also correlated our results from the blood DNA methylation analysis with 
previously published findings on AD-associated DNA methylation markers in the 
brain. However, only two of the eleven regions, the ones closest to DEAF1 and 
DEFA1 genes, we identified with RRBS in the blood are targeted in Illumina 450K 
methylation arrays, which have been used in the previous studies. On the other hand, 
previously identified AD DNA methylation marker regions, for example, ANK1 and 
RHBDF2, were not detected in our RRBS data. (De Jager et al., 2014; Lunnon et al., 
2014; Smith, Smith, Burrage, et al., 2019) 
Discussion 
 59 
6.6 Plasma cell-free DNA methylation marks for 
episodic memory impairment 
A new method was implemented for the analysis and DNA methylation profiles were 
characterised from as little as three nanograms of plasma DNA. All in all, the amount 
of DNA that we were able to isolate from the plasma samples and the number of 
CpG sites we detected from the bisulphite sequencing libraries, was quite low. This 
indicates that there is no major leak of free DNA from the degenerating neuronal 
cells into blood circulation at this early stage of memory impairment. Majority of the 
methylation sites we detected in the plasma DNA samples were located in the 
telomere and centromere regions of most of the chromosomes, showing that these 
regions are for some reason heavily represented in the plasma. It may be that 
centromere and telomere regions are more stable and resistant to enzymatic 
degradation due to condensed packing of the chromatin, in comparison to other 
genomic regions. 
We found no statistically significant differences in the plasma circulating cfDNA 
methylomes associated with EM impairment. This indicates that the degenerating 
neuronal cells do not release free DNA into the peripheral blood circulation at this 
stage of cognitive impairment, or the cfDNA degrades so quickly in plasma that it 
cannot be measured. However, the number of discordant twin pairs included in the 
differential methylation analysis was very limited: only four pairs, and, to our 
knowledge, this has not been studied elsewhere either. Thus, a more comprehensive 
comparison of a larger study population is needed to form more reliable conclusions. 
However, as the number of detected CpG sites varied remarkably between 
individuals and only 2.089 sites were detected in all individuals, our results indicate 
that the inter-individual variety in plasma cfDNA populations makes it difficult to 
compare cfDNA methylation profiles of larger groups of individuals. We initially 
selected the seven twin pairs for this comparison according to primary knowledge 
on their cognitive status and discordance. The twin pairs were recruited for imaging 
studies and neurophysiological testing in Turku PET centre using a telephone 
questionnaire (Järvenpää et al., 2002). However, at the time when we had already 
processed the samples for plasma cfDNA methylation analysis, the 
neurophysiological test results revealed that only four of the seven twin pairs were 
discordant according to aMCI criteria. 
The custom whole-genome bisulphite sequencing method was successfully 
implemented in this project. However, there are a few uncertainties to take into 
consideration. The overall number of CpG sites detected with sufficient sequencing 
coverage was quite low. Of course, this may also be due to a biological characteristic 
of the samples and there are no more DNA fragments or CpG sites to be detected in 
plasma cfDNA. When implementing the library preparation method, we also looked 
into the effect of starting DNA amount on the final library quality. According to the 
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results, the starting DNA amount has little to no impact on the number of detected 
CpG sites in the final library. This indicates that only a very small portion of the 
genome is present as cfDNA in the plasma. However, more research is also needed 
in this field as there are no comprehensive reports about the genomic coverage when 
sequencing plasma cfDNA. 
The processing of the plasma DNA methylation sequencing data proved to be 
more challenging than we expected. Mapping of short read bisulphite sequencing 
data is difficult because bisulphite conversion reaction decreases the nucleotide 
sequence complexity of the sequencing reads. Thus, a high proportion of the 
sequencing reads can be identical and align perfectly with several different genomic 
locations, when mapped to a reference genome, which would cause bias in the 
sequencing results. By default, sequencing reads that align with several different 
genomic locations, in other words non-uniquely mapped reads, are discarded from 
the data after data pre-processing and mapping. Yet even from our uniquely mapped 
reads, which align only with one unique genomic location, a large proportion aligned 
with genomic regions like centromeres and telomeres that often consist of simple 
DNA sequences and repeating elements. These regions share high sequence 
similarity even between different chromosomes while the short repeating regions 
may differ between individuals, making bisulphite sequencing read mapping 
unreliable. 
Due to the possible reliability issue in sequencing read mapping, we decided to 
exclude the reads aligning with repeating DNA elements from the data, which 
decreased the number of detected CpG sites by half of what was initially in the data. 
While this was probably the best option, a lot of data was lost and it is also possible 
that these regions would contain interesting information. Mapping this kind of 
bisulphite sequencing data would require more inspection. This problem has only 
arisen after the release of the newest human reference genome hg38 since many of 
the low sequence-complexity genomic regions were not included in the previous 
versions. Also, we did not find any published studies that would describe the 
mapping of plasma cfDNA bisulphite sequencing data, making it impossible to 
compare our data to others’, even though similar methods have been utilised before 
in studies on other diseases and biological conditions. Plasma cfDNA methylation 
marks have been studied as potential biomarkers for prenatal diagnostics, detection 
of different cancers and assessment of organ transplant rejection, for example (Lun 
et al., 2013; Sun et al., 2015; Guo et al., 2017). 
In conclusion, we found no differences in plasma cfDNA methylation of twin 
pairs discordant for EM function. However, a more comprehensive comparison of a 
larger number of samples is required to validate or disprove these results. While the 
method that we implemented and utilised in the plasma DNA methylation analysis 
seemed to work well, a more comprehensive comparison of sequencing coverage 
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and read mapping between our method and other similar methods would be advised 
before utilising it in a larger sample cohort. 
6.7 DNA methylation marks in hESCs and patient-
derived iPSCs and brain organoid models 
RRBS analysis of hESCs before and after transformation to abnormal karyotype 
revealed epigenetic silencing of the CAT gene, which encodes an important 
antioxidant enzyme. Although further studies are required to elucidate whether this 
alteration regulates genomic integrity, the finding provides a valuable marker of 
epigenetic integrity of hPSC lines for further studies and helps the identification of 
cell lines prone to accumulate genomic abnormalities. 
Patient-derived iPSC lines were generated from PBMCs and the method to 
generate 3D cerebral organoids was successfully implemented. Cerebral organoids 
were generated from hESC lines. The initial goal was to utilise this approach in 
modelling AD in vitro and examine how epigenetic changes contribute to the disease 
mechanisms. During the progression of this study, however, findings by other 
research groups revealed that cerebral organoid models recapitulate the phenotype 
of developing foetal brain and require a lot more development before they can be 
utilised in modelling adult neurodegenerative diseases. Therefore, the project was 
put on hold until methods enabling in vitro ageing of the models have emerged (Luo 
et al., 2016). 
6.8 Future perspectives 
We detected peripheral blood DNA methylation differences at eleven genomic 
regions in Finnish twin pairs discordant for AD. One of these DMRs, which located 
in the ADARB2 gene, was validated in an extended cohort, including Swedish twins. 
Targeted validation would be required for the other DMR regions as well to more 
precisely evaluate their value for AD diagnostics. Since the methylation marker in 
the ADARB2 gene is on its own not sensitive enough for AD diagnosis, targeted 
validation of the other regions would also enable characterising whether a combined 
analysis of several of the DMRs increases the diagnosis sensitivity to a sufficient 
level or not. It would also be interesting to see if these peripheral blood methylation 
markers are specific for AD or are they present in other dementias and cognitive 
disorders as well. After all, an AD biomarker should be specific for the disease and 
enable differential diagnosis from other dementias and neurodegenerative disorders. 
More research is also needed to find out how the differentially methylated genes 
are involved in AD pathogenesis. Studying the pathogenic mechanisms of AD has 
been very difficult. The recent discoveries in stem cell research have produced new 
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tools, like patient-derived iPSC lines and cerebral organoids, which are valuable for 
studying neuronal development and functions. However, even these have limitations 
in modelling neurodegenerative diseases, like AD, that develop during a time-span 
of tens of years. While iPSC lines have been derived from AD patients and these 
cells have disturbances in molecular mechanisms associated with AD, like amyloid-
β and tau processing, the in vitro stem cell and organoid cultures are simplified 
models of very complicated neuronal tissues that are degenerating in AD. Besides, 
the in vitro neuronal cell and organoid cultures can only be maintained for a limited 
amount of time. Thus, they model neuronal cell and tissue development at relatively 
early stages making it currently impossible to study the effects of ageing and external 
factors over time that are very important in AD pathogenesis. (Lancaster et al., 2013; 
Lee et al., 2016; Raja et al., 2016; Gonzalez et al., 2018) The initial goal of the stem 
cell project was to establish neuronal cell and cerebral organoid cultures from 
patient-derived iPSC lines and study how epigenetic mechanisms and the marker 
genes discovered in peripheral blood DNA methylation analysis of discordant twin 
pairs impact AD pathogenesis. However, the organoid cultures were successfully 
implemented using hESC lines and this method can be invaluable in other research 
projects studying, for example, neurodevelopmental disorders and defects. 
There is an urgent need for reliable AD models, was it human stem cell or 
animal-derived, to better characterise the molecular pathogenic changes that trigger 
the neurodegeneration in the disease. Even though there are similarities between 
different AD cases, like the disturbances in the processing of amyloid-β and tau, the 
disease is indeed multifactorial and the factors that trigger the disease may vary 
between individuals. Thus, patient-derived iPSC lines and disease models will be 
invaluable in molecular AD research to characterise the similarities and differences 
between individual AD cases in the future, even though the current utility of these 
models in AD research is limited.
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7 Conclusions 
The main goal of this study was to identify peripheral blood DNA methylation 
markers for AD and EM impairment. To achieve this goal, several methods were 
implemented to analyse genome-wide DNA methylation profiles from the human 
cell and tissue samples and to validate the findings in a targeted manner. The RRBS 
method was successfully implemented for genome-wide DNA methylation analysis 
of hESC, human brain tissue and blood samples. The RRBS results from hESC lines 
were validated by comparing DNA methylation profiles and mRNA and protein 
levels, as we discovered that expression of an important antioxidant enzyme, 
catalase, is silenced in abnormal cells via increased DNA methylation. RRBS was 
further utilised in characterising DNA methylation markers associated with AD in 
peripheral blood and brain tissue. 
We detected peripheral blood DNA methylation differences in Finnish twin pairs 
discordant for AD at eleven genomic regions. One of the DMRs was also validated 
in the blood of discordant Swedish twin pairs and brain tissue from non-twin 
American AD cases versus controls. Thus, the results show that DNA methylation 
markers for the disease can be detected in peripheral blood, and correlate with AD-
associated DNA methylation marks in the brain. According to our results, the 
methylation markers do not associate with gene expression differences in blood 
between AD patients and controls. More research is required to characterise how 
these methylation differences and the affected genes contribute to AD, which can 
give new insights to the disease pathogenesis in the future. Further studies are also 
needed to find out whether a peripheral blood DNA methylation marker or a 
combination of several markers could be sensitive and specific enough to be utilised 
in clinical AD diagnosis. 
We found no methylation differences in the circulating plasma cfDNA fraction 
in twin pairs discordant for EM performance. However, in the course of this study, 
we collected a valuable twin sample cohort, including blood, plasma and PBMC 
samples from 40 individuals and PBMC-derived iPSC lines from three individuals. 
This sample cohort can be utilised in studying new peripheral blood biomarkers for 
EM impairment and functional changes in iPSC derived neuronal cell and tissue 
development in the future. A human PSC derived cerebral organoid tissue model was 
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implemented for studying epigenetic changes and molecular mechanisms in AD, 
however; due to current limitations in the methodology the models are more suitable 
for studying early nervous tissue development rather than progressive 
neurodegeneration. Furthermore, all the genome and epigenome research methods 
that were implemented during this PhD project are available for the customers of 
Finnish Functional Genomics Centre. 
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